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ABSTRACT 
Cell signaling is an essential function of cells and tissues. Understanding cell signaling 
necessitates technologies that can identify protein-protein interactions as well as post 
translational modifications to proteins within protein complexes. The goals of this study 
are (1) to understand how BCR-ABL variants differentially signal to produce 
different clinical/experimental phenotypes and (2) to develop novel interactome 
detection strategies to understand signaling. This dissertation describes an integrated 
approach of the use of proximity dependent labeling protein-protein interaction analysis 
assays coupled with global phosphorylation analysis to investigate the differences in 
signaling between two variants the oncogenic fusion protein, BCR-ABL. Two major types 
of leukemogenic BCR-ABL fusion proteins are p190BCR-ABL and p210BCR-ABL.  Although the 
two fusion proteins are closely related, they can lead to different clinical outcomes. A 
thorough understanding of the signaling programs employed by these two fusion proteins 
is necessary to explain these clinical differences. Our findings suggest that p190BCR-ABL and 
p210BCR-ABL differentially activate important signaling pathways, such as JAK-STAT, and 
engage with molecules that indicate interaction with different subcellular compartments.  
In the case of p210BCR-ABL, we observed an increased engagement of molecules active 
proximal to the membrane and in the case of p190BCR-ABL, an engagement of molecules of 
the cytoskeleton. These differences in signaling could underlie the distinct leukemogenic 
process induced by these two protein variants. Additionally, this dissertation also describes 
the development of a novel interactome detection strategy, called Biotinylation Site 
Identification Technology (BioSITe), which increases the sensitivity and specificity of 
proximity dependent biotin labeling technologies. When applied to BCR-ABL variants, 
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BioSITe provides structural information about BCR-ABL interacting proteins and the 
degree of proximity these proteins are to BCR-ABL. Finally, this thesis demonstrates the 
use of isotopically labeled biotin for quantitative BioSITe experiments, applied to BCR-











Graduate Advisor: Karen Reddy Ph.D.., Professor, Department of Biological Chemistry 
and Center for Epigenetics  
 
Graduate Advisor: Akhilesh Pandey, M.D. Ph.D., Professor, McKusick-Nathans 









This dissertation is the product of seven years of intensive research and molecular 
biology and genetics education which exemplifies the multidisciplinary nature of the 
Human Genetics training program at the Johns Hopkins University School of Medicine. 
The Human Genetics training program curriculum has provided me a strong foundation 
in one of the few true fundamentals of biology, genetics. Building upon the unique 
pedagogy cultivated by the faculty within the Institute of Genetic medicine whose goal is 
to understand human genetic variation and disease I have become a proud and skillful 
scientist. Of course, my two incredible thesis mentors, Karen Reddy and Akhilesh 
Pandey, have had the most intimate hand in shaping my experience of obtaining my PhD 
by providing an immense amount of material support, nourishment as a thinking scientist, 
and technical training. Certainly, co-mentorship has its challenges and while the interests 
of the Reddy and Pandey labs are disparate in the end Karen and Akhilesh put me in a 
privileged position to influence the direction of both labs.  Both Karen and Akhilesh gave 
me wide room to explore many different aspects of molecular biology and stuck with me 
when things didn’t work and helped me flourish when they did. Being in two labs has 
given me the opportunity to learn a more diverse set of technologies that I wouldn’t have 
overwise in only one lab. Most of all both Karen and Akhilesh have taught me how to 
critically think about and pursue scientific questions. Both approach science in different 
ways and it was an immensely great experience to benefit from these different 
approaches. I truly admire both Karen and Akhilesh for their innovative and forward 
thinking scientific pursuits and their openness toward collaborations in science, for which 
 vi 
I have benefited immensely from. I look forward to continue that collaborative spirit 
throughout my career.  
A special thanks to Dr. Oliver Hantschel and Dr. Reckel Sina Maren who were 
working on the same BCR-ABL signaling story as myself and had the humility to 
coordinate our efforts so that we could publish back-to-back in Leukemia.  It was an 
incredible experience to work with Sina and Oliver and they ended up co-authors on the 
BioSITe paper, contributing an important analysis. Another special thanks to Dr. Dae In 
Kim who I worked very closely with to produce the BioSITe paper.  It was a wonderful 
collaborative experience to work with Dae In. I’d also like to thank Dr. Curt Civin who 
has been a mentor from afar (across town at University of Maryland) from the first month 
I arrived in Baltimore Curt has been an invaluable resource for navigating science, 
Baltimore, and beyond.  Curt was instrumental in helping me find a post doctorate 
position and has heaped so much praise upon me that has lifted my spirits and sense of 
self on many occasions.  I’d also like to thank Curt for initiating the collaboration with a 
colleague of his Dr. Tami Kingsbury, who I’ve gotten the opportunity to work on her 
exciting project.    
I would like to thank my thesis committee, Dr. Steven Desiderio, Dr. Hans 
Bjornsson, and Dr. Patrick Brown, for all of their valuable insight and guidance over the 
course of my PhD. I am especially grateful to the generosity, support, and friendship I 
received from previous and current lab members of the Reddy and Pandey lab.  Members 
including Tai-Chung Haung, Min-Sik Kim, Chris Mitchell, Teresa Luperchio, Xianrong 
Wong, Mo Heydarian, Raiha Tahir, Xinyan Wu, Saddiq Zahari, Tori Hoskins, Chan-
Hyun Na, and many others.  I would like to especially thank my undergraduate research 
 vii 
mentors, Dr. Michael Loken and Dr. Denise Wells, for recognizing my potential to 
become a scientist and fomenting my interest in hematopoiesis.  
I would also like to thank my incredibly supportive family of Denise, Mike, 
Harvey, Roselyn, Krista, Sara, and Zach. I’d also like to thank Rachel, the mother of our 
two children Veja and Ivo, for being game to move to Baltimore and start a family with 
me, during the trying times of graduate school.  Rachel’s day-to-day presence was 
probably the single greatest impact on my happiness.  Of course, Veja and Ivo also share 
in that as they are the most sweet and wonderful little bubs ever.  
Many thanks to Sandy Muscelli for her excellent skills as an administrator, her 
kindness, sense of humor, and the many pretzels she provided me. Sandy’s support 
throughout the years has been invaluable and her allowance of a very reasonable part of 
the program budget for me to organize some great happy hours has been wonderful. I’d 
like to thank Dr. Dave Valle for his incredible leadership of the Human Genetics Training 
Program, his excellence in teaching genetic medicine and his valuable historical 
knowledge of the field of genetics. I’d also like to thank the Department of Biological 
Chemistry for their support during my graduate career, especially Dr. Gerry Hart’s 




TABLE OF CONTENTS 
ABSTRACT .................................................................................................................. ii 
DISSERTATION REFEREES ........................................................................................... iv 
ACKNOWLEDGEMENTS ............................................................................................... v 
TABLE OF CONTENTS ................................................................................................ viii 
LIST OF FIGURES ........................................................................................................ xi 
LIST OF ABBREVIATIONS ............................................................................................xii 
CHAPTER 1. ................................................................................................................ 1 
INTRODUCTION .......................................................................................................... 1 
CHAPTER 2. .............................................................................................................. 14 
MATERIALS AND METHODS ...................................................................................... 14 
CHAPTER 3. .............................................................................................................. 31 
DIFFERENTIAL SIGNALING THROUGH BCR-ABL VARIANT FUSION PROTEINS .............. 31 
3.1 Experimental rationale .................................................................................... 32 
3.2 Establishment of BioID system to examine BCR-ABL interactome in Ba/F3 cells 32 
3.3 A common BCR-ABL interactome signature ...................................................... 34 
3.4 p190BCR-ABL and p210BCR-ABL display differential interactions with proteins in 
different cellular compartments ............................................................................ 36 
3.5 p190BCR-ABL and p210BCR-ABL interaction analysis in MPP cells ............................. 39 
 ix 
3.6 Global phosphorylation signatures of p190BCR-ABL and p210BCR-ABL in Ba/F3 cells 40 
3.7 Cytoskeleton proteins hyperphosphorylated in p190BCR-ABL expressing cells ...... 42 
3.8 Phosphorylation signatures of p210BCR-ABL expressing cells ............................... 44 
3.9 Differential regulation of Stat proteins ............................................................ 46 
3.10 Correlation of global phosphorylation signatures between p190BCR-ABL/p210BCR-
ABL in the MPP and Ba/F3 cells: .............................................................................. 47 
3.11 The integration of interactome and phosphorylation data highlights differently 
regulated molecules by p190BCR-ABL and p210BCR-ABL ................................................ 48 
3.12 In a multipotent background p190BCR-ABL and p210BCR-ABL regulate total protein 
levels of important hematopoietic drivers differently ............................................ 51 
CHAPTER 4. .............................................................................................................. 53 
BioSITe: A METHOD FOR DIRECT DETECTION AND QUANTITIATION OF SITE -SPECIFIC 
BIOTINYLATION ........................................................................................................ 53 
4.1 Proximity dependent labeling technologies do not detect biotinylated proteins
 ............................................................................................................................. 54 
4.2 Detection of biotinylated peptides using BioSITe ............................................. 54 
4.3 Mapping of biotinylation sites in proteins ........................................................ 58 
4.4 Application of BioSITe for quantitative proteomics .......................................... 61 
4.5 Applying BioSITe to the APEX system ............................................................... 62 
4.6 Biotinylation site-dependent topology prediction ............................................ 65 
4.7 Applying BioSITe to biotin-based click chemistry .............................................. 68 
CHAPTER 5. .............................................................................................................. 70 
 x 
DISCUSSION ............................................................................................................. 70 
5.1 BCR-ABL variant signaling ................................................................................ 71 
5.2 BioSITe conclusions and future of interactomics .............................................. 77 
BIBLIOGRAPHY ......................................................................................................... 81 
CURRICULUM VITAE ................................................................................................. 88 
 
 xi 
LIST OF FIGURES 
 
Chapter 1 
Figure 1.1 ………………………………………………………………………………3 
Figure 1.2 ………………………………………………………………………………5 
Figure 1.3 ………………………………………………………………………………8 
 
Chapter 3 
Figure 3.1 ………………………………………………………………………………33 
Figure 3.2 ………………………………………………………………………………35 
Figure 3.3 ………………………………………………………………………………41 
Figure 3.4 ………………………………………………………………………………50 
 
Chapter 4 
Figure 4.1 ………………………………………………………………………………56 
Figure 4.2 ………………………………………………………………………………60 
Figure 4.3 ………………………………………………………………………………63 
Figure 4.4 ………………………………………………………………………………66 
 
Chapter 5 
Figure 5.1 ………………………………………………………………………………74 
Figure 5.2 ………………………………………………………………………………79  
 xii 
LIST OF ABBREVIATIONS  
ABL   Abelson tyrosine kinase 
Abi1   Abl interactor 1 
Acap1 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing 
protein 1 
Arap1 Arf-GAP with a rho-GAP domain, ANK repeat and PH domain-
containing protein 1 
Arap3 Arf-GAP with a rho-GAP domain, ANK repeat and PH domain-
containing protein 3 
Arhgef6  rho guanine nucleotide exchange factor 6 
Arhgdia   rho GDP-dissociation inhibitor 1 
Arid3a  AT-rich interactive domain-containing protein 3A 
BCR   breakpoint cluster region  
BioSITe  Biotin Site Identification Technology 
B-ALL  B cell acute lymphoblastic leukemia 
Cbl   Cbl proto-oncogene 
Cblb   Casitas B-lineage lymphoma b 
Clnk   cytokine dependent hematopoietic cell linker 
CML   chronic myelogenous leukemia 
Crk   CRK proto-oncogene adaptor protein 
Csk   tyrosine protein kinase Csk 
Dab2ip   DAB2 interacting protein 
DH   Dbl homology 
 xiii 
DiDBiT  Direct Detection of Biotin-containing Tags 
Dok1   Docking protein 1 
E2A   transcription factor E2-alpha 
GAPs   GTPase-activating proteins 
Gab2   Grb2-associated-binding protein 2 
GEF    guanine nucleotide exchange factors 
GFP   green fluorescent protein 
Grb2    growth factor receptor-bound protein 2 
IRES   internal ribosome entry site 
HSC   hematopoietic stem cell 
LC-MS/MS  liquid chromatography and tandem mass spectrometry 
Lyn   tyrosine protein kinase Lyn 
Lrrk1   leucine rich repeat kinase 1 
MLL-r  mixed lineage leukemia rearrangements  
Nck1   Nck adaptor protein 1  
Nck2   Nck adaptor protein 2  
Peak1   pseudopodium-enriched atypical kinase 1 
PH   Pleckstrin Homology domain 
PTM   post translational modification 
PPI   protein-protein interaction  
PDLTs  proximity dependent labeling technologies 
pTyr   phosphotyrosine    
Ptpn11  Tyrosine-protein phosphatase non-receptor type 11 
 xiv 
RUNX1  runt related transcription factor 1 
RUNX3  runt related transcription factor 3 
Sch1   SHC-transforming protein 1 
shRNA  short hairpin RNA 
SHIP1   phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1  
SHIP2   inositol Polyphosphate Phosphatase Like 1 
Sipa1   signal-induced proliferation-associated protein 1 
Sia1l11  signal-induced proliferation-associated 1-like protein 1 
STAT   signal transducer and activator of transcription 
Sos1   son of sevenless homolog 1 
Sos2   son of sevenless homolog 2 
Syk   tyrosine protein kinase Syk 
Tnk2   tyrosine kinase non-receptor 2 
Ubash3b  ubiquitin-associated and SH3 domain-containing protein B 
Vav1   proto-oncogene Vav 1 
WAS   Wiskott aldrich syndrome 
WASP   Wiskott aldrich syndrome protein 
Wasf2   WAS Protein Family Member 2 
Wipf1   WAS/WASL-interacting protein family member 1 
Wipf2   WAS/WASL-interacting protein family member 1 











Cell signaling is an essential function of cells and tissues.  Cells respond to 
environmental signals and via signal transduction translate these signal into the 
augmentation of cellular processes to carry out important biological functions.   The 
molecular events that underline signal transduction interest scientists and clinicians 
because many times these events are abnormally altered in the state of disease.  
Furthermore, these molecular events hold promise to be pharmacologically targeted to 
provide important therapies.  The study of cell signaling has a long history of innovation 
and breakthroughs1. Undoubtedly, one of the most studied molecular events that mediate 
signal transduction has been the regulation of post translation modifications (PTMs) of 
proteins.  While there are close to 200 different known PTMs, phosphorylation is perhaps 
the most studied and importantly appears to be involved in all cellular processes. 
Phosphorylation is a reversible modification to the serine, threonine and tyrosine amino 
acids on proteins that is mediated by kinases and phosphatases that phosphorylate and 
dephosphorylate, respectively, target proteins.  The cascade of 
phosphorylation/dephosphorylation events allow cells to transmit signals from 
environmental stimulus to alter the function of proteins that control important cellular 
functions that range from cytoskeleton reorganization to changes in gene expression 
(Figure 1.1).  
Another essential molecular event that governs signal transduction if protein-protein 
interactions (PPIs).  The function of an individual protein cannot be understood without 
an understanding of what other proteins it is in close proximity to or physically interacts 




Figure 1.1 Simplified model of signal transduction mediated by PPIs. Depiction signal 
transduction in response to a stimulus, in this case a ligand binding to a receptor. A generalized 
receptor shown in dark blue binds ligand (yellow) causes a conformational change allowing new 
PPIs that bring together kinases, green and brown, and substrates, red and brown.  Subsequently, 
the activated kinases produce a phosphorylation, red circle labeled P, cascade that transmits 
downstream phosphorylation events that affect protein functions that result in altered cellular 
functions.  Protein complexes mediating signal transduction are depicted by closely place proteins.    
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an affinity for the protein it can phosphorylate but also the proteins that aid increasing the 
efficiency of this reaction, often referred to as adapter proteins.  Recently, advances in the 
study of PPIs using in-cell proximity dependent labeling technologies (PDLTs) have 
shown promise to change the conventional understanding of PPIs.  Based on the simple 
concept of tethering a engineered biotin ligase to a protein of interest and expressing this 
fusion protein, PDLTs such as the BioID and APEX systems are being rapidly deployed 
by researchers to study PPIs as well as subcellular proteome mapping2.  Both the BioID 
and APEX systems leverage biotin ligases that produce short lived and highly reactive 
biotin adducts that only diffuse a short distance from the active site of the ligase giving 
both systems the ability to selectively label only proximal proteins. The APEX system 
leverages an engineered ascorbate peroxidase enzyme designated APEX2 that uses 
hydrogen peroxide to catalyze the transfer of biotin-phenol to tyrosine residues in 
proteins3,4.   BioID, similarly relies on an engineered biotin ligase called BirA*5,6 to 
generate biotinoyl-5′-AMP which is reactive with lysine residues of proteins 7. The 
labeling time is starkly different in the BioID systems compared to the APEX system, 
BioID requires 18-24 hours of exogenous biotin incubation to achieve complete labeling 
and the APEX system can modify proximal proteins with exogenously provided biotin 
phenol in 30 seconds to 1 minute of labeling time (Figure 1.2). These systems have three 
important advantages to traditional methods (1) labeling is controllable by adding 
exogenous biotin (2) labeling is carried out under cellular conditions with sub-cellular 
structures intact providing more biologically relevant conditions with no in-vitro bias (3) 
sample preparation can be made uniform and reproducibly carried out lab-to-lab. When 
compared to traditional methods to study PPIs it is clear that proximity dependent 
 5 
 
Figure 1.2 Overview of proximity dependent labeling technologies. Depiction the BioID and 
APEX systems to detect proximal proteins using in cell biotin labeling technologies.  BioID system, 
top left, relies on the engineered biotin ligase BirA*, which requires exogenous biotin (B in red 
circle) and ATP to biotinylate proximal proteins in and 18-24 hour period. APEX system, bottom 
left, relies on the engineered biotin ligase APEX2, which requires exogenous biotin phenol (BP in 
red circle) and hydrogen peroxide (H2O2) to biotinylate proximal proteins. A generalized workflow 
for identifying proximal proteins in both APEX and BioID systems is depicted on the right. Cells 
harboring APEX and BioID systems are lysed and enriched for biotinylated proteins and 
subsequently digested into peptides for LC-MS/MS analysis. Biotinylated proteins are labelled with 
B or BP in red circles and non-biotinylated proteins are removed with strong denaturing conditions. 
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labelling technologies detect a distinct, “complimentary” and “biologically meaningful” 
subset of the interactions of the protein of interest8.   
Both the APEX and BioID system have been coupled to liquid chromatography and 
tandem mass spectrometry (LC-MS/MS) as the mode of detection of interacting proteins.    
Generally speaking, the study of protein-protein interactions and phosphorylation has 
taken a major leap forward with the advent of so-called “shotgun proteomics” using LC-
MS/MS9. Where historically studying protein involved low throughput methods, mostly 
antibody based, to detect single proteins and single PTMs, LC-MS/MS allows for high-
throughput simultaneous detection of thousands of proteins and PTMs. Shotgun 
proteomic approaches rely on enzymatic, usually trypsin, digestion of proteins into 
peptides that can be identified by LC-MS/MS followed by database search of resulting 
mass spectra.  
The broad biological interest of my thesis work is rooted in the hematopoietic system and 
the leukemias that arise from this system. More specifically, my thesis work focuses on 
how signaling drives the leukemic process.  The hematopoietic system, simply put, is the 
responsible for the formation of cells that comprise blood.  The hematopoietic stem cell 
(HSC) resides in the bone marrow and gives rise to many different cell types that are 
responsible for incredibly diverse functions throughout the body. The hematopoietic 
system is constantly active, meaning cell divisions is a constant producing hundreds of 
billions cells a day.  A subset of these cells that are on my interest to my thesis work are 
lymphocytes.  Lymphocytes in the presence of genetic mutations can produce a wide 
variety of cancers including, and of most interest to my thesis work, leukemia.  Leukemia 
can arise from many different stages of maturation from the HSC and can retain 
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phenotypes characteristics of normal cells giving rise to nomenclature that helps 
clinicians stratify and treat these various types of leukemia (Figure 1.3). One such subset 
of leukemia, B cell acute lymphoblastic leukemia (B-ALL), is of particular interest to my 
thesis work because of many of the underlining genetic mutations produce fusion proteins 
that have fascinating biology and important clinician characteristics that pose challenges 
to treat.  My thesis work focuses on one such mutation that results from a chromosomal 
translocation that produces the fusion gene known as BCR-ABL.  BCR-ABL is most 
famously associated chronic myelogenous leukemia (CML), which has very good 
outcome because of targeted treatments (cite), but is also associated with B-ALL which 
has inferior prognosis.   
Throughout hematopoietic development differentiating cells respond to cytokines and 
other signals that provide the stimulus for correct development.  These signaling 
pathways are subverted and/or altered in leukemic cells which underlines a major 
mechanism of leukemogenesis and leukemic maintenance10.  In Chapter 2 (methods) and 
Chapter 3 I will describe a set of experiments using the BioID system and global 
phosphorylation profiling to interrogate outstanding questions related how the BCR-ABL 
oncogene through signaling can differently generate B-ALL and CML. Chromosomal 
translocations involving the breakpoint cluster region (BCR) and Abelson murine 
leukemia viral oncogene homolog 1 (ABL) genes generate BCR-ABL, a potent oncogene 
that drives leukemia.  Depending upon the exact breakpoint of translocation within the 
BCR gene, distinct fusion genes leading to different fusion proteins are generated.  The 
most common translocations generate fusion protein products with molecular weights of 
190 and 210 kD.11   
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Figure 1.3  Simplified schematic of hematopoiesis and leukemogenesis. Depiction of different 
stages of hematopoietic maturation derived from the hematopoietic stem cell (HSC). Orange 
lightning strikes represent DNA mutations to either progenitor or HSC populations that give rise to 
leukemia.  Examples of leukemia with phenotypic characteristics of different lineages are listed, 
acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), Acute promyelocytic 
leukemia (APL), myelodysplastic syndromes, B-cell acute lymphoblastic leukemia (B-ALL), T-
cell acute lymphoblastic leukemia (T-ALL), and aggressive NK-cell leukemia (ANKL). 
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These variants, designated as p190 and p210 (hereafter referred to as p190BCR-ABL and 
p210BCR-ABL), are associated with distinct clinical features.12  Generally, p190BCR-ABL leads 
to ALL while the p210BCR-ABL variant leads to CML.  The two types of leukemia driven by 
these variants exhibit different treatment response to chemotherapy including tyrosine 
kinase inhibitors leading to distinct clinical outcomes.13,14  The reasons for this discrepancy 
are still not fully understood.   
BCR-ABL fusion genes code for proteins with constitutively active tyrosine kinase activity 
that mediate transformation by inducing signaling pathways that enhance cell growth and 
evade normal regulation.  Despite numerous studies into the mechanisms underlying 
p190BCR-ABL and p210BCR-ABL induced leukemia, the fundamental questions of whether and 
how these proteins engage different signaling programs remain unanswered.  The major 
structural difference between the two variants is the presence two domains commonly 
found in guanine nucleotide exchange factors (GEFs); a Dbl homology (DH) domain 
followed by a Pleckstrin homology domain (PH) in p210BCR-ABL.  Dbl homology domains 
have catalytic GEF activity and PH domains facilitate intercellular targeting including 
plasma membrane binding.  Ablation of the DH domain’s GEF activity or deletion of the 
PH domain results in phenotypes similar to p190BCR-ABL, suggesting that both domains may 
be essential for sustaining p210BCR-ABL-specific phenotypes.12,15  Direct comparison of 
p190BCR-ABL and p210BCR-ABL in in vitro kinase activity assays has shown p190BCR-ABL to 
exhibit higher auto-phosphorylation, leading to the conclusion that p190BCR-ABL is likely a 
more active kinase.16,17  Several studies have analyzed signaling pathways induced by 
BCR-ABL (reviewed in Hantschel18 and Cilloni et al.19) although, studies directly 
comparing signaling differences between p190BCR-ABL and p210BCR-ABL are more 
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limited.12,20,21  A few studies have examined global phosphorylation events induced by 
either p190BCR-ABL or p210BCR-ABL,22–24 but to date no study has directly compared the 
differential signaling patterns induced by these two variants in the same cellular 
environment.   Similarly, very little is known about the potential protein-protein interaction 
differences that mediate p190BCR-ABL and p210BCR-ABL specific signaling.  The p210BCR-ABL 
“core” interactome has been previously catalogued25 but, to date, there are no reports of 
direct comparisons between p190BCR-ABL and p210BCR-ABL interactomes.    
In order to test the hypothesis that p190BCR-ABL and p210BCR-ABL leverage different protein 
partners and induce different signaling programs, we decided to express these proteins in 
the same cell type. We chose an early hematopoietic progenitor model, the well-studied 
Ba/F3 cell line, to directly compare the differential signaling and protein-protein 
interactome of the two variants.  We used the BioID system to identify protein-protein 
interactions and phosphotyrosine (pTyr) peptide enrichment to identify site specific 
tyrosine phosphorylation events on target proteins.  An integrative analysis of the 
interactome and phosphorylation data allowed us to discover overlapping and differential 
signaling pathways.  Specifically, we found an increased interaction of p210BCR-ABL with 
membrane-proximal signaling proteins including ubiquitin-associated and SH3 domain-
containing protein B (Ubash3b or Sts-1) and phosphatidylinositol 3,4,5-trisphosphate 5-
phosphatase 1 (Inpp5d or SHIP1), with both proteins displaying increased phosphorylation 
in p210BCR-ABL harboring cells.  p190BCR-ABL, on the other hand, displayed increased 
interaction and phosphorylation of many cytoskeletal proteins, including members of the 
Wiskott-Aldrich syndrome protein family.  In agreement with previous studies, we also 
observed differential p190BCR-ABL and p210BCR-ABL phosphorylation signatures of signal 
 11 
transducer and activator of transcription (Stat) proteins. In addition, our study provides 
evidence for differential phosphorylation of Stat proteins at the level of individual tyrosine 
phosphorylation sites, which could be mediated by differential interactions.  Our findings 
reveal that p190BCR-ABL and p210BCR-ABL have both overlapping and different specificities 
for substrates, potentially interact with different subcellular compartments and mediate 
differential downstream signaling events that ultimately lead to different clinical outcomes.   
 
As described above PPIs are essential to understand the function of proteins. Developing 
novel methods to detect PPIs is of great importance.  Building upon the work of integrated 
analysis of BCR-ABL variant interactome and phosphorylation profiles, Chapter 2 
(methods) and Chapter 4 describe the development of a method to detect biotinylated 
peptides to improve upon PDLTs.  Mapping PPIs and subcellular proteomes is an important 
strategy to reveal biological phenomena and mechanisms of disease. As described above 
the newly developed proximity-dependent biotinylation methods such as APEX and BioID 
facilitate discovery of PPIs and subcellular proteomes within living cells. The identification 
of biotinylated proteins that are generated using these strategies has hitherto relied upon 
capture using the streptavidin family of proteins followed by either on-bead digestion or 
in-gel digestion followed by LC-MS/MS analysis. While these methods have been used 
successfully they both necessitate the use of identified non-biotinylated peptides as 
surrogates for biotinylation, as biotinylated peptides are rarely, if at all, detected. The 
reason non-biotinylated peptides are rarely identified is that the way that the strong affinity 
of streptavidin for biotin is used largely precludes it. In in-gel digestion elution of 
biotinylated proteins is required. Several elution methods have been developed, either 
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using detergent26, extremely low pH27 or solvents28 and alternative strategies have been 
employed including weakened affinity of streptavidin/avidin to biotin through chemical29 
or genetic30 means have also been described. However, all approaches yield partial 
recovery of biotinylated proteins from streptavidin31 and when elution followed by in-gel 
digestion is applied in proximity-dependent biotinylation experiments non-biotinylated 
peptides vastly out number biotinylated peptides3. The need for good elution strategies has 
been circumvented by the use of on-bead digestion which is a convenient and widely used 
method in proximity-dependent biotinylation experiments. However, biotinylated peptides 
are left bound to beads and remain undetected as the streptavidin-biotin interaction is not 
disrupted. In a different approach, which does not suffer from the limitations just described, 
Schiapparelli et al. previously described a strategy designated DiDBiT (Direct Detection 
of Biotin-containing Tags) where they first digested proteins into peptides and then 
enriched biotinylated peptides using NeutrAvidin32. Because this method was mostly tested 
using proteins biotinylated in vitro we reasoned that the strong affinity of NeutrAvidin for 
biotin could still limit detection of biotinylated peptides, especially in the context of in vivo 
biotinylation such as in proximity-dependent biotinylation methods, where the overall level 
of biotinylation level might be low. 
To improve the biotinylated peptide detection issue, we have developed a strategy 
designated Biotinylation Site Identification Technology (BioSITe), which is based on the 
use of anti-biotin antibodies to directly capture and identify biotinylated peptides in a 
single LC-MS/MS run.  We developed BioSITe using BCR-ABL variant system 
described in Chapter 3 but also apply it to a well-established APEX based system of 
subcellular proteome mapping of compartments of the mitochondria. We show that 
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detection of biotinylated peptides greatly increases the confidence of candidate protein 
identification in proximity-dependent biotinylation methods. By providing the site of 
biotinylation on proteins labeled in these methods, this approach also offers a new level 
of information about the structural aspects of PPIs and protein topology. Finally, we 
describe a simple approach for quantitative BioSITe experiments through the use of 
isotopically labeled biotin obviating the use of metabolic labeling based quantitative 






CHAPTER 2.  
MATERIALS AND METHODS 
  
 15 
2.1 Plasmids, cloning, antibodies, and reagents 
The mouse retroviral vector pMSCV modified with an IRES-GFP containing either the 
p190BCR-ABL or the p210BCR-ABL form of BCR-ABL was provided by Saradhi Mallampati 
and Xiaoping Sun.  The plasmid pcDNA3.1 myc-BioID containing the mutant BirA-
R118G was purchased through Addgene (Plasmid #35700).  BirA was cloned in-frame 
on the N-terminus of both p190BCR-ABL and p210BCR-ABL to generate BirA-R118G- 
p190BCR-ABL-IRES-GFP-pMSCV and BirA-R118G-p210BCR-ABL-IRES-GFP-pMSCV. A 
fragment between the AUG start codon and an XhoI site within the common part of BCR 
in p190BCR-ABL and p210BCR-ABL was PCR amplified with flanking restriction sites for 5’ 
XhoI-HpaI and 3’ SalI-XhoI.  Parent plasmids were restriction digested with to XhoI to 
remove 147 bases upstream of the AUG, the PCR product was ligated in its place.  The 
p190BCR-ABL and p210BCR-ABL plasmids now missing 147 base pairs 5’ of the AUG were 
digested with blunt end restriction enzyme HpaI.  The plasmid pcDNA3.1 myc-BioID 
containing the mutant BirA-R118G was purchased through Addgene (Plasmid #35700).  
The plasmid pcDNA3.1 myc-BioID containing the mutant BirA-R118G was purchased 
through Addgene (Plasmid #35700) was restriction digested with NheI and BamHI to 
excise BirA-R118G.  This fragment was blunt end cloned into the HpaI site of p190BCR-
ABL and p210BCR-ABL making, in-frame, BirA-R118G- p190BCR-ABL-IRES-GFP-pMSCV and 
BirA-R118G-p210BCR-ABL-IRES-GFP-pMSCV.  SILAC amino acids were purchased from 
Cambridge Isotopes; heavy (lysine-13C6,15N2 #CNLM-291, arginine-13C6,15N4 #CNLM-
539) and medium (lysine-13C4 #CLM-2247, arginine-13C6 #CLM-2265) labels were 
dissolved in arginine and lysine deficient RPMI 1640 medium, then sterile filtered.  A 
complete list of antibodies used: α-ABL1 (emdMillipore #MABT203), α-WIP/WIPF1 
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(emdMillipore #MABS1275), α-WASP (Cell Signaling Technology(CST) #4860), α-
phospho-WASP (Tyr290) (Abcam #59278), α-Ubash3b/STS-1 (Santa Cruz Biotech. sc-
514612), α-SHIP1 (CST #2728), α-Stat1 (CST #9172), α-phospho-Stat1 (Tyr701) (CST 
#7649), α-Stat5b (Santa Cruz Biotech. sc-1656), α-phospho-Stat5 (Tyr694) (CST #9359), 
α-Stat6 (Santa Cruz Biotech. sc-374021), α-phospho-STAT6 (Tyr641) (Abcam 
#125308), α-DOK1 (Santa Cruz Biotech. sc-6929), α-phospho-DOK1 (Tyr362) (Abcam 
#47374), α-Cbl (Santa Cruz Biotech. sc-170), and α-β-Actin (CST #4970) Anti-biotin 
antibody 1 (Abcam, #ab53494), anti-biotin antibody 2 (Bethyl Laboratories,#150-109A), 
streptavidin-HRP (Abcam, #ab7403), protein G beads (EMD Millipore, #16-266), high 
capacity neutrAvidin agarose (Thermo Fisher Scientific, #29202), biotin (Sigma Aldrich, 
#B4501), biotin-2’,2’,3’,3’-d4 (Sigma Aldrich, #809068), lipofectamine 2000 (Thermo 
Fisher Scientific, #11668019), biotin-phenol (Iris Biotech, #CDX-B0270-M100), 
sequencing grade trypsin (Promega, #V5113 ), GalT1 enzymatic labeling kit (Invitrogen, 
#C33368), PNGase F (New England Biolabs, #P0704S), (Thermo Fisher Scientific, 
#C10412) and trypsin (Worthington Biochemical Corporation, #LS003741). 
2.2 BioID: biotinylated protein capture, on bead digestion, and Western blotting 
validation:  
Methods used for execution of the BioID experiment were an amalgamation of protocols 
from the Roux and Gingras groups8,34 with slight modifications to both. Cells destined for 
BioID protocols were cultured for 24 hours in 50 μM biotin containing culture medium.  
Lysis was carried out in BioID lysis buffer (50 mM Tris, pH 7.5, 500 mM NaCl, 0.4% 
SDS, 2% Triton X-100 with Halt™ protease inhibitors) by probe sonication as described 
above.  After the first round of sonication, the sample was diluted with equal volume of 
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50mM Tris, target protein concentration was 5 mg/ml.  Lysates were quantified by BCA 
and dithiotheritol (DTT) was added to a final concentration of 1 mM for the pulldown.  A 
ratio of 4 mg of lysate per 300uls of MyOne™ Dynabeads® Streptavidin C1 (#65001) to 
5 µg of trypsin per replicate was used for all mass spectrometry experiments.   For label-
free experiments 4 mg per IP replicate was used.  For SILAC experiments 8 mg per cell 
line was mixed.  An aliquot of input was collected for western blot analysis and lysate/bead 
slurry was rotated overnight at 4°C, aliquot of the flow-through was collected.  All bead 
washes were in 1.3 mL; 2 times with 2% SDS, 50 mM Tris, pH 7.5 followed by 2 washes 
with bioID lysis buffer, and finally 3 washes of 50 mM ammonium bicarbonate (ABC).  
On the third wash 10% of the total bead slurry was aliquot for boiling elution with 1X 
Laemmli Sample Buffer (Bio-Rad #1610747) with 20mM DTT for immunoblotting.  
Additional streptavidin isolates were generated by elution for validation of mass 
spectrometry data by immunoblotting. The rest of the bead slurry was subjected to on-bead 
digestion.  Wash buffer was removed and beads were spun down and resuspended in 50 μl 
of 8 M UREA, 50 mM ABC, pH 8.0 to denature the bound proteins.  Proteins were reduced 
by adding 5 μl of 1 M DTT and incubating at 30°C for 60 minutes, then samples were 
alkylation by adding 5 μl of 0.5M iodoacetamide in the dark for 30 minutes.  The volume 
was then increased to 400 μl with 50 mM ABC pH 8.0 containing 5 µg of sequencing grade 
trypsin.  Digestion was allowed to go overnight on a shaker kept at 30°C.  The beads were 
removed from the digest solution and washed once with 50 μl of 50 mM ABC and all beads 
removed, the solution was pooled.  The final 450 μl was acidified to 1% trifluoroacetic 
acid, spun at 18,000xg and loaded on to a C18 homemade stage tip for clean-up, stage-
protocol was based on previously published methods. 
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2.3 Cell Culture and generation of stable cell lines:  
Mouse retroviral packaging cell line Platinum-E was cultured in high-Glucose Dulbecco’s 
modified Eagle’s medium (Gibco #11995073) supplemented with 10% FBS 
(ThermoFisher #26140079).  The mouse hematopoietic cell line Ba/F3 was cultured in 
RPMI 1640 (ThermoFisher #11875119) supplemented with 10% FBS in the presence of 
the cytokine IL-3 (0.5 ng/mL).  The mouse MPP cell line generated from Ebf1-/- were 
cultured on OP-9 stromal cells in Opti-MEM I Reduced Serum Medium (ThermoFisher 
#31985088) supplemented with 5% FBS, 1% penicillin-streptomycin, 2 mM glutamine, 
beta/mercaptoethanol (1:1000 dilution).  MPP cultures were grown in the presence of IL-
7 (5 ng/mL; CST #5217SC), Scf (10 ng/mL; CST #5223SC), and Flt3l (10 ng/mL; R&D 
systems #427-FL-025)35,36.   
Plasmid DNA from either p190-IRES-GFP-pMSCV, p210-IRES-GFP-pMSCV, BirA-
R118G-p190-IRES-GFP-pMSCV, or BirA-R118G-p210-IRES-GFP-pMSCV was 
transfected into Platinum-E using the Fugene HD Transfection Reagent (Promega 
#E2311).  Viral supernatant was collected at multiple time points and pooled.  Ba/F3 and 
MPP cell lines were subjugated to spinfection mediated retroviral transduction.  Two 
million cells from each cell line were resupended in 1 mL of viral supernatant with 
cytokines and polybrene (1 µg/mL) then centrifuged in a 24-well plate at 2000xg for 2 
hours at 24°C.  The cells were returned to a 37°C incubation for a 2-hour recovery.  Cells 
were then washed with PBS and returned to normal cytokine containing medium and in the 
case of MPP cells were returned to OP-9 stromal cells.  Following a 24 hour incubation 
transduction efficiency was confirmed using flow cytometry to quantify GFP expression.  
Cells were then washed with PBS to remove all cytokines and returned to culture 
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conditions without cytokines or stromal cells to select for growth factor independence.  
MPP cells expressing p190BCR-ABL or p210BCR-ABL were transitioned into SILAC RPMI 
1640 (ThermoFisher #89984), for pTyr experiment, Ba/F3 BirA-p190BCR-ABL, BirA-p210 
BCR-ABL, and parental cells were also transitioned to SILAC RPMI, otherwise all cells were 
grown in their respective medium.  All cell lines when used in proteomic analysis were 
washed in large volumes of PBS at least 3 times and pelleted and snap frozen with liquid 
nitrogen.  
2.4 Peptide preparation and phosphopeptide enrichment:  
Frozen SILAC Labeled cell pellets were lysed in 9 M urea buffer with protease inhibitors 
(Halt™ Cocktail ThermoFisher #78429), sodium pyrophosphate (2.5 mM), sodium 
orthovanadate (1 mM), sodium fluoride (5 mM), β-glycerophosphate (1 mM) by 3 rounds 
of probe sonication (duty cycle 30%, 20 two second pulses).  Protein concentration of 
lysates was determined by Pierce™ BCA Protein Assay Kit.  Twenty milligrams of 
protein lysates from each labeling condition was mixed and subjected to trypsin in-
solution digestion, followed by lyophilization. A total of 60mg and 40 mg for the BAF3 
and MPP experiment, respectively, per replicate of lyophilized tryptic peptides were used 
for phosphotyrosine enrichment using PTMScan® Phospho-Tyrosine rabbit monoclonal 
antibody kit (P-Tyr-1000) (Cell Signaling Technology, #8803). Anti-phosphotyrosine 
immunoprecipitation was carried out following the manufacturer’s instructions.  A 300 
μg aliquot of SILAC mix was also subjected to a separate in-solution tryptic digestion 
and was fractionated by basic reverse phase liquid chromatography into 12 fractions and 
analyzed by LC-MS/MS. For BioSITe and other peptide enrichment experiments, cells 
were lysed using a lysis buffer containing 50 mM TEABC and 8 M Urea and sonication 
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as described above. The protein concentration of samples was measured by BCA assay 
and the protein concentration of APEX lysate was estimated by cell number. Reduction 
and alkylation were performed by serial incubation with 10 mM DTT for 30 min and by 
20 mM IAA for 30 min in the dark. Lysate was diluted to 2 M Urea by adding three cell 
lysate volumes of 50 mM TEABC. The proteins were digested with trypsin (1:20 of 
trypsin to protein) at 37°C overnight. The resulting tryptic peptides for both experiments 
were desalted using a Sep-PAK C18 and subsequently lyophilized. 
For on-bead digest, neutravidin beads were centrifuged and resuspended in 100 μL of 50 
mM TEABC and 2 M UREA. Reduction and alkylation of captured proteins was 
performed by incubation with 10 mM dithiothreitol (DTT) for 60 min and by 20 mM 
iodoacetamide (IAA) in the dark for 30 min. The volume was then increased to 200 μL 
with 50 mM TEABC pH 8.0 containing 3 µg of sequencing grade trypsin.  Overnight 
digestion carried out on a shaker maintained at 37°C. The supernatant was collected and 
the beads were washed once with 50 μL of 50 mM TEABC, which was collected and 
pooled. The final 450 μL was acidified to 1% trifluoroacetic acid, spun at 18,000 x g and 
was desalted with a homemade reversed-phase C18 column following stage-protocol 
previously published methods. In experiments designed to enrich biotinylated proteins 
using anti-biotin antibodies, after elution, the samples were dried and resuspended in 2 M 
Urea in 50 mM TEABC and digested with 3 μg of trypsin and desalted using a C18 
column. 
For BioSITe experiments the fractionated peptides were analyzed on an Orbitrap Fusion 
Lumos Tribrid Mass spectrometer coupled with the Easy-nLC 1200 nano-flow liquid 
chromatography system (Thermo Fisher Scientific). The peptides from each fraction were 
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reconstituted in 20 μL 0.1% formic acid and loaded onto an Acclaim PepMap 100 Nano-
Trap Column (100 μm x 2 cm, Thermo Fisher Scientific) packed with 5 μm C18 particles 
at a flow rate of 4 μl per minute. Peptides were separated at 300-nl/min flow rate using a 
linear gradient of 7% to 30% solvent B (0.1% formic acid in 95% acetonitrile) over 95 
min on an EASY-Spray column (50 cm x 75 µm ID, Thermo Fisher Scientific) packed 
with 2 µm C18 particles, which was fitted with an EASY-Spray ion source that was 
operated at a voltage of 2.3 kV. 
Mass spectrometry analysis was carried out in a data-dependent manner with a full scan 
in the mass-to-charge ratio (m/z) range of 300-1,800 in the “Top Speed” setting, three 
seconds per cycle. MS and MS/MS were acquired for the precursor ion detection and 
peptide fragmentation ion detection, respectively. MS scans were measured at a 
resolution of 120,000 at an m/z of 200. MS/MS scans were acquired by fragmenting 
precursor ions using the higher-energy collisional dissociation (HCD) method and 
detected at a mass resolution of 30,000, at an m/z of 200. Automatic gain control for MS 
was set to one million ions and for MS/MS was set to 0.05 million ions. A maximum ion 
injection time was set to 50 ms for MS and 100 ms for MS/MS. MS was acquired in 
profile mode and MS/MS was acquired in centroid mode. Higher-energy collisional 
dissociation was set to 32 for MS/MS. Dynamic exclusion was set to 35 seconds, and 
singly-charged ions were rejected. Internal calibration was carried out using the lock 
mass option (m/z 445.1200025) from ambient air. Data acquisition of click chemistry-
modified O-GlcNAc modified peptides were carried out using alternate HCD/ETD 
(electron transfer dissociation) method. 
2.5 BioID and APEX preparation and lysis: 
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BioID was performed essentially as described Roux et al. with some minor modifications. 
Ten mg of protein per replicate was incubated with 200 μL of high capacity neutravidin 
for overnight at 4 ºC. After overnight incubation with 50 μM biotin, Ba/F3 cells 
expressing BirA*-BCR-ABL p190 were lysed in BioID lysis buffer (50 mM Tris, pH 7.5, 
500 mM NaCl, 0.4 % SDS, 2 % Triton X-100 with Halt™ protease inhibitors) followed 
by sonication (3 rounds, duty cycle 30%, 20 second pulses). After cleaning, the samples 
were centrifuged at 16,000 x g for 10 min, equal volumes of 50 mM Tris were added to 
the BioID samples. Lysates were quantified by bicinchoninic acid (BCA) assay and 10 
mg of protein per replicate was incubated with 200 μL of high capacity neutravidin 
overnight at 4 C. After incubation, the bead slurry was washed with 2% SDS, 50 mM 
Tris three times, BioID lysis buffer three times and 50 mM Tris three times and 50 mM 
triethylammonium bicarbonate (TEABC) three times. Cells used for experiments to 
enrich biotinylated proteins using anti-biotin antibodies were lysed in the same buffer 
used in the BioSITe strategy and the biotinylated proteins were captured and eluted in the 
same manner as described for BioSITe experiments. The experiments were carried out in 
triplicate using 10 mg of proteins per replicate. 
APEX was performed as described by Hung et al. APEX-IMS and APEX-NES were 
transiently transfected into HEK293 using Lipofectamine 2000. One day later, the 
transfected cells were incubated with 50 µM biotin-phenol for 30 min and then with 1 
mM H2O2 for 1 minute at room temperature. The APEX reaction was subsequently 
quenched by washing cells with quenching solution containing 10 mM sodium ascorbate, 
5 mM Trolox and 10 mM sodium azide in PBS. Cells were collected by scrapping and 
pelleted.  
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2.6 Direct detection of biotin-containing tags: 
This procedure was carried out as described by Schiapparelli et al. Ten mg of peptides 
generated from cells expressing BirA*-BCR-ABL p190 were dissolved in 1 mL of PBS 
and incubated with 90 μL of high capacity neutravidin beads for 1 hour at room 
temperature. Bead slurry was sequentially washed with PBS three times, 5 % acetonitrile 
three times and ultrapure water three times. Captured peptides were eluted by adding the 
elution buffer containing 0.2 % trifluoroacetic acid, 0.1 % formic acid, and 80 % 
acetonitrile. Peptides were eluted with and without boiling for 5 min for a total of 10 
elutions which were pooled and desalted using a de-salting column as previously 
described. 
2.7 BioSITe: 
 For each replicate, 10 mg of total protein from BirA*-BCR-ABL cells was digested into 
peptides and incubated with biotin-specific antibodies bound to protein G beads. For 
APEX samples, 8 mg of total protein was used per each replicate and digested into 
peptides. The bead slurry was sequentially thoroughly washed. Biotinylated peptides 
were eluted four times. Anti-biotin antibodies (100 μg) were coupled with 120 μL of 
protein G bead slurry for overnight at 4 °C. Antibody coupled beads were further washed 
with PBS once and BioSITe capture buffer (50 mM Tris, 150 mM NaCl, 0.5% Triton X-
100) twice. Peptides were dissolved in 1 mL of BioSITe capture buffer. After dissolving 
peptides, pH was adjusted to neutral (7.0-7.5) and peptide BCA was preformed to 
estimate peptide concentration. Peptides were subsequently incubated with biotin 
antibody coupled protein G beads for 2 hours at 4 °C. The bead slurry was sequentially 
washed two times with BioSITe capture buffer, two times with 50 ml Tris and two times 
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with ultrapure water. Biotinylated peptides were eluted four times using elution buffer 
(80% acetonitrile and 0.2% trifluoroacetic acid in water). The eluent was further cleaned 
up using C18 reversed-phase column as previously described.  
2.8 BioSITe for quantitative proteomics:  
Peptides from the combined samples were subjected to BioSITe analysis. Cells 
expressing BirA*-BCR-ABL p190 or BirA*-BCR-ABL p210 were cultured overnight 
with 50 mM heavy or light biotin, respectively. The cells were lysed equal amounts from 
each condition were mixed to generate a total of 10 mg sample, which was digested, 
desalted, lyophilized and subjected to BioSITe as described above.  
Biotinylation of O-GlcNAc sites using click-it chemistry- HEK293 cells were treated with 
500 nm thiamet-G for 4 hrs to enhance the overall O-GlcNAcylation levels by inhibiting 
O-GlcNAcase (OGA), an enzyme that removes O-GlcNAc. Peptides were generated as 
previously described and in-solution Lys-C digestion was carried out overnight at 37°C. 
The peptide digest was then cleaned up using C18 solid phase extraction cartridge. The 
cleaned peptides were then vacuum dried and labeled with tandem mass tags. O-GlcNAc 
sites on these peptides were modified in-vitro using GalT1 enzymatic labeling kit. 
Briefly, peptides were reconstituted in 1.1 ml of 20 mM HEPES (pH 7.9), and 80 ul of 
100 mM MnCl2, 75 ul of 0.5 mM UDP-GalNAz, 62ul of GalT1 and 5 ul of PNGase F. 
The mixture was then incubated overnight at 4°C. The peptides were then reacted with 
10uM DIBO Biotin-Alkyne in a copper-free Click-IT chemistry labeling of azides at 
room temperature for 1 hour. The peptides were then cleaned using C18 solid phase 
extraction cartridge followed by strong-cation exchange SPE and then vacuum dried. The 
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O-GlcNAc-modified and Click-IT labeled peptides were then subjected to BioSITe-based 
enrichment. 
2.9 Mass spectrometry data analysis and post-processing and bioinformatics:  
Peptides from on-bead digests of streptavidin captured biotinylated proteins, 
phosphotyrosine immunoprecipitation, and total protein lysates were analyzed using a 
nanoflow UPLC system (Easy nanoLC 1200, Thermo Scientific) interfaced with Orbitrap 
Fusion Lumos mass spectrometer (Thermo Scientific) equipped with an EasySpray ion 
source. In total, 39 fractions from different BioID interactome enrichment experiments, 
anti-phosphotyrosine immunoprecipitation, and total protein experiments were analyzed 
by mass spectrometry. Three replicates of pTyr enrichment experiments, 12 bRPLC total 
protein fractions, 3 replicate streptavidin captures (run twice per replicate) comprised the 
experiments carried out in Ba/F3 cells.  Similarly, 3 replicates of pTyr enrichments, 12 
bRPLC total protein fractions, 6 replicates of label-free streptavidin captures comprised 
experiments in multi-potent progenitor (MPP) cells 
Proteome Discoverer software suite (v 2.1; Thermo Fisher Scientific) was used for 
quantitation and database searches. The MS/MS data were searched using the SEQUEST 
search algorithm against a Mouse RefSeq database (v73 containing 58,485 entries) 
supplemented with frequently observed contaminants.  Additionally, the BirA-p190BCR-ABL 
sequence, which represents the common sequence of p190BCR-ABL and p210BCR-ABL and the 
p210BCR-ABL specific sequence (DH and PH domain) were added to the database, as separate 
entries.  The search parameters used for SEQUEST are listed in Supplemental Methods. 
The PSMs, peptides and proteins were filtered at 1% false discovery rate cut-off calculated 
using decoy database searches. After database searching, SILAC ratios of peptides were 
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quantified with PyQuant.37  For label-free analysis of the MPP BioID experiment,  
MaxQuant software package with default settings was used.38  Parameters used for 
SEQUEST search algorithm included trypsin as protease with full specific and a maximum 
of one allowed missed cleavage; carbamidomethylation of cysteine as a fixed modification; 
oxidation at methionine and biotinylation at Lysine as variable modification. In case of 
phosphotyrosine immunoprecipitation data analysis phosphorylation at tyrosine was 
selected as variable modification. For all the 3-State SILAC labeled samples, 13C6, 15N2-
lysine, 2H4-lysine, 13C6-arginine and 13C6, 15N4-arginine as variable modifications. The 
precursor tolerance was set at 10 ppm while the fragment match tolerance was set to 0.1 
Da. 
In-house python scripts (https://github.com/pandeylab/pythomics) were used for post-
processing annotation, protein inference, and normalization of the SILAC data.  To 
correct for loading biases in the SILAC mixes in the pTyr experiments, we normalized 
the data based on the total protein measurements from 12 bRPLC fractions.  Total protein 
was normalized to the median and that correction factor was applied to all values in pTyr 
data.  After normalization, the total protein SILAC ratios for all peptides mapping to 
individual proteins were grouped and the median value was calculated for protein level 
measurements.  For pTyr data, SILAC ratios were maintained at the peptide level and 
grouped by site, and median values were calculated, SILAC ratios for pTyr values were 
adjusted based on the corresponding abundance value from the total protein data that the 
phosphosite mapped.  Additional median normalization was applied to the p190BCR-
ABL/p210BCR-ABL ratio as p190BCR-ABL cells were observed to have a slight increase in global 
phosphorylation compared to p210 BCR-ABL cells in the Ba/F3 experiment, the opposite was 
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observed in MPP experiment and was normalization similarly.  Finally, when a 
phosphorylation site was sampled in all three replicates, the median was calculated, in the 
case of phosphorylation sites sampled in only two replicates, the average was taken.  The 
SILAC BioID data followed a similar scheme although based on the ratios of known 
endogenously biotinylated proteins being near equally represented in the p190BCR-
ABL/p210BCR-ABL cells, no normalization was applied to the data.  Median values of 
replicates were calculated when sampled in all three replicates and average was used for 
sampling in 2 replicates.  No correction was applied for abundance values differences 
from the total protein.  BioID data went through a series of filtering steps to eliminate 
potential false-positive interactors.  Specifically, we first compared all putative 
interacting proteins (irrespective of BCR-ABL variant) to a negative control streptavidin 
capture consisting of non-BirA Ba/F3 lysate to screen for endogenously biotinylated 
proteins.  Next, we referenced the CRAPome database39 to identify and remove proteins 
with a higher likelihood of being non-specific in pull-down assays, to further filter 
potential non-specific protein interactors.  Then proteins were filtered if they were not 
sampled in at least 2 of the replicates.  We followed these initial filtering steps with 
STRING analysis,40 a tool to search interaction networks between proteins based on 
previous studies, on the remaining protein identities to identify those proteins with known 
interactions by biochemical evidence.  This analysis revealed a major node comprising of 
many known BCR-ABL interactors, indicating the robustness of our assay in detecting 
these interactions.  Our final set of protein interactors after the filtering was comprised of 
90 proteins. For BioSITe experiments Proteome Discoverer (v 2.1; Thermo Scientific) 
suite was used for quantitation and identification using all 3 replicate LC-MS/MS runs 
 28 
per experiment searched together. Spectrum selector was used to import spectrum from 
raw file. During MS/MS preprocessing, the top 10 peaks in each window of 100 m/z 
were selected for database search. The tandem mass spectrometry data were then 
searched using SEQUEST algorithm against protein databases (For BioID experiments; 
mouse NCBI RefSeq 73 (58,039 entries) with the addition of fasta file entries for BCR-
ABL p190 and the DH and PH domain of BCR-ABL p210, for APEX experiments; 
human NCBI RefSeq (73,198 entries) with the additions of fasta file entries of IMS-
APEX2 and NES-APEX2 constructs) with common contaminant proteins. The search 
parameters for identification of biotinylated peptides were as follows: a) trypsin as a 
proteolytic enzyme (with up to three missed cleavages); b) peptide mass error tolerance 
of 10 ppm; c) fragment mass error tolerance of 0.02 Da; and d) carbamidomethylation of 
cysteine (+57.02146 Da) as a fixed modification and oxidation of methionine 
(+15.99492 Da) and biotinylation of lysine (+226.07759 Da) as variable modifications. 
The search parameters for the identification of biotin-phenol modified peptides were as 
follows: a) trypsin as a proteolytic enzyme (with up to two missed cleavages); b) peptide 
mass error tolerance of 10 ppm; c) fragment mass error tolerance of 0.02 Da; and d) 
carbamidomethylation of cysteine (+57.02146 Da) as a fixed modification and oxidation 
of methionine (+15.99492 Da). Biotinylation of lysine (+226.07759 Da), biotin-phenol 
modification of tyrosine (+361.14601 Da), and oxidized-biotin-phenol modification of 
tyrosine (+377.141 Da) were all used as variable modifications. For the identification and 
quantification of the peptides modified by light or heavy biotin, all the raw files from the 
three replicates were searched together. The search parameters for identification of either 
light or heavy biotinylated peptides were as follows: a) trypsin as a proteolytic enzyme 
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(with up to three missed cleavages); b) peptide mass error tolerance of 10 ppm; c) 
fragment mass error tolerance of 0.02 Da; and d) carbamidomethylation of cysteine 
(+57.02146 Da) as a fixed modification and oxidation of methionine (+15.99492 Da), 
light biotinylation of lysine (+226.07759 Da) and heavy biotinylation of lysine (+230.103 
Da) as variable modifications. The minimum peptide length was set to 6 amino acids. For 
identification of click chemistry-modified O-GlcNAcylated peptides, apart from 
Oxidation of methionine and Carbamidomethylation of Cysteine, variable modification of 
click label (993.36 Da i.e. HexNAc+GalNAz+DIBO alkyne biotin) on serine and 
threonine residues were included in database search. Peptides and proteins were filtered 
at a 1% false-discovery rate (FDR) at the PSM level using percolator node and at the 
protein level using protein FDR validator node, respectively. 
The protein quantification was performed with following parameters and methods. The 
heavy to light ratios of the biotinylated peptides were measured by the Precursor Ions 
Quantifier node. Unique and razor peptides both were used for peptide quantification 
while protein groups were considered for peptide uniqueness. Precursor ion abundance 
was computed based on intensity and the missing intensity values were replaced with the 
minimum value. Protein grouping was performed with strict parsimony principle to 
generate the final protein groups. All proteins sharing the same set or subset of identified 
peptides were grouped while protein groups with no unique peptides were filtered out. 
The Proteome Discoverer iterated through all spectra and selected PSM with the highest 
number of unambiguous and unique peptides. 
Identified protein and peptide spectral match (PSM) level data were exported as tabular 
files from Proteome Discoverer 2.1. We used an in-house Python script to compile the 
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peptide level site information mapped to UniProt or RefSeq databases.  The summary 
count on number of supported peptides and PSMs are then calculated at protein level. In 
case of the heavy-biotin experiment, the ratios are calculated from total channel 
intensities of identified peptides. 
2.10 Protein modeling:  
The degree and location of biotinylation as well as the protein domain organization were 
assigned based on information in UniProt (uniprot.org) taking into account the protein 
size, number of total lysines and domain annotation according to PROSITE and InterPro 
databases. To map biotinylation sites on three-dimensional structures, structural models 
were obtained from the Protein Data Bank (PDB, rcsb.org) as far as available or 
homology models were created using Swiss-Model (swissmodel.expasy.org). 
2.11 Data availability:  
All mass spectrometry data and search results have been deposited to the 
ProteomeXchange Consortium) via the PRIDE partner repository with the dataset identifier 
PXS005209 and PXD007862. 
2.12 Experimental Design and Statistical Rationale: 
 All experiments described in this study were performed as three independent replicates 
from the same starting material (process replicates). Because this is a new method, this 
replicate design was employed to account for sampling bias. A qualitative comparison of 
the identifications from the methods being compared was done in all cases except in the 









DIFFERENTIAL SIGNALING THROUGH BCR-ABL 
VARIANT FUSION PROTEINS  
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The following work was published in the journal Leukemia and all reference to 
supplemental data/figures can be found at the Leukemia website with the following this 
citation41.   
3.1 Experimental rationale  
Both p190BCR-ABL and p210BCR-ABL are constitutively active kinases with similar 
molecular makeup that differ only by the presence (p210BCR-ABL) or absence (p190BCR-ABL) 
of a DH and PH domain (Figure 1a).  Given the differences in clinical outcomes, we 
hypothesized that these two proteins display differential binding of partner proteins and 
phosphorylation signatures leading to distinct downstream signaling pathways.  We 
therefore employed a two-pronged approach by expressing the variants in the same 
cellular background, the well-studied murine hematopoietic Ba/F3 cell line. The first part 
of our approach relied on detecting differential protein-protein interactions 
(“interactome”) of these two proteins by using BioID coupled with mass spectrometry 
and SILAC-based quantitation (Figure 1b). The second part involved investigation of  
differential global phosphorylation signatures (“phosphoproteome”) via pTyr peptide 
enrichment followed by mass spectrometry and SILAC-based quantitation42 (Figure 1c).   
3.2 Establishment of BioID system to examine BCR-ABL interactome in Ba/F3 cells 
BioID can detect both transient interactions as well as more stable interactions. 
When the promiscuous biotin ligase (BirA) is cloned in-frame with a protein of interest, it 
biotinylates interacting proteins including those that are transiently bound, enabling 
detection of interacting proteins via enrichment by streptavidin.43  We cloned BirA onto 
the N-terminus of both p190BCR-ABL and p210BCR-ABL because we reasoned that this 
positions the BirA moiety most proximal to differing domains of p190BCR-ABL and   
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Figure 3.1 Strategy for investigating BCR-ABL interactome and phosphoproteome. (a) 
Domain structures of p190BCR-ABL and p210BCR-ABL are shown. The lack of Dbl homology (DH) and 
Pleckstrin homology (PH) domain in the BCR part of the p190BCR-ABL variant is indicated by dashed 
lines.  The biotin ligase, BirA, was cloned in-frame at the N-terminus of both variants as indicated. 
The domains shared by the two variants are coiled-coiled (CC), BCR serine/threonine Kinase (S/T 
Kinase), Src homology 3 (SH3), Src Homology 2 (SH2) Abl Tyrosine Kinase (TyrK), and F-Actin 
Binding Domain (F-Actin BD). (b) The experimental workflow for interactome analysis by BioID 
in Ba/F3 cells.  Both BCR-ABL cell lines were grown in SILAC containing K4R6(medium) or 
K8R10 (heavy) amino acids, exogenous biotin was added to both cultures as indicated and 
incubated for 24 hours.  The resulting lysates were subjected to streptavidin capture followed by 
trypsin digestion and LC-MS/MS.  (c)  The experimental workflow for phosphoproteome analysis 
in Ba/F3 cells.  Cells were grown in SILAC media containing K0R0 (light), K4R6 (medium), or 
K8R10 (heavy) amino acids. The parental line was cytokine starved and the cultures harvested, 
lysed, mixed, and trypsin digested.  A small fraction of the lysate was fractionated by reversed 
phase liquid chromatography (bRPLC) and analyzed by LC-MS/MS. The remaining peptides were 
immunoprecipitated with pY1000 antibody and subjected to LC-MS/MS analysis.  (d) Western 
Blot analysis with antibodies against Abl and β-Actin showing the relative expression levels of the 
two variants in Ba/F3 cells.  (e)  Addition of BirA does not alter the ability of BCR-ABL to drive 
cytokine independence in Ba/F3 cells:  Flow cytometry plots monitoring GFP expression versus 
side scatter in Ba/F3 cells expressing BCR-ABL isoforms with or without BirA after retroviral 
transduction and post IL-3 withdrawal are shown.   
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p210BCR-ABL (Figure 1a).  Relative expression levels of BirA tagged p190BCR-ABL and 
p210BCR-ABL proteins were analyzed by immunoblot (Figure 1d).  In agreement with 
previous studies in which expression of BCR-ABL in Ba/F3 cells induced IL-3 
independence,44 the BirA tagged versions of both p190BCR-ABL and p210BCR-ABL also 
induced cytokine independence (Figure 3.1e).  In order to detect interacting proteins, 
these cells were cultured in the presence of exogenous biotin to induce in vivo labeling of 
BCR-ABL variant interactors. These cells were then lysed, mixed and three independent 
experiments were performed to enrich biotinylated proteins by streptavidin capture under 
denaturing conditions, followed by trypsin digestion. The resulting peptide mixture was 
then subjected to LC-MS/MS analysis (Figure 3.1b).  As expected, a substantial 
enrichment of biotinylated proteins as well as the capture of BCR-ABL variants was 
observed in the streptavidin isolates (Supplemental Figure 1a).  A total of 814 proteins 
were identified by LC-MS/MS analysis, of which 308 proteins were detected in all three 
replicates and their corresponding SILAC ratios are plotted in Figure 3.2a (Supplemental 
Table 1 for complete data). Additional streptavidin isolates were generated for 
immunoblot based validation of targets identified in the mass spectrometry data (Figure 
3.2b).    
3.3 A common BCR-ABL interactome signature 
First, we identified the overall BCR-ABL interactome within our BioID 
experiment by employing filtering steps to remove non-specific interactions and identify 
well supported interactions using literature-based tools (see Materials and Methods).  
This analysis resulted in a subset of 90 proteins, whose SILAC ratios are represented in  
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Figure 3.2 Interactome analysis of BCR-ABL variants using the BioID system. (a) A plot of 
SILAC ratios (log2 scale) for the detected proteins in Ba/F3 interactome analysis. Endogenously 
biotinylated proteins are shown.  (b) Western blot validation of Ba/F3 mass spectrometry BioID 
data. Biotinylated proteins captured by streptavidin from the indicated cells were probed with 
antibodies against Cbl, Inpp5d/SHIP1, Stat1, Was/WASP, and β-Actin as shown in the right panel. 
The whole cell lysate is also probed in parallel (left panel).   (c) Heat map of select BCR-ABL 
interacting proteins along with any observed enrichment in one or the other BCR-ABL isoform is 
shown.  (d) Venn diagram of the BCR-ABL core interactome observed in our analysis of Ba/F3 
and MPP cells. Within the green are overlapping interactors that were detected in both MPP and 
Ba/F3 cells.  Interactors in white are either cell type specific or not sampled in the cell type.  Gene 
symbols for overlapping p190BCR-ABL enriched and p210BCR-ABL enriched interactions are underlined. 
(e) Western blot validation of MPP mass spectrometry BioID data. Biotinylated proteins captured 
by streptavidin from the indicated cells were probed with antibodies against Wipf1, Ubash3b, Stat1, 
Cbl, and β-Actin as shown in the right panel. The whole cell lysate is also probed in parallel (left 
panel).     
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the heat map in Figure 2c. This subset includes many known BCR-ABL interactors 
including Nck adaptor protein 1 (Nck1), Nck adaptor protein 2 (Nck2), Docking protein 1 
(Dok1), Tyrosine-protein phosphatase non-receptor type 11 (Ptpn11), Son of sevenless 
homolog 1 and 2 (Sos1, Sos2), Abl interactor 1 (Abi1), Grb2-associated-binding protein 
2 (Gab2), and Pseudopodium-enriched atypical kinase (Peak1), among others.  We also 
confirmed previously defined components of the BCR-ABL interactome25 in our 
analysis: Growth factor receptor-bound protein 2 (Grb2), SHC-transforming protein 1 
(Shc1), CRK proto-oncogene adaptor protein (Crk), Cbl proto-oncogene (Cbl), 
phosphoinositide-3-kinase regulatory subunit 2,  Ubash3b, and Inositol Polyphosphate 
Phosphatase Like 1 (Inppl1 or SHIP2) (Figure 3.2d and Supplemental Table 1).    
3.4 p190BCR-ABL and p210BCR-ABL display differential interactions with proteins in 
different cellular compartments 
In order to characterize the differential interactome of p190BCR-ABL and p210BCR-
ABL, we measured SILAC ratios of peptides from interacting biotinylated proteins 
captured from the two variants.  We defined p190BCR-ABL enriched interactions as proteins 
with SILAC ratios indicating greater than 1.8-fold enrichment in p190BCR-ABL, while ratios 
indicating greater than 1.8-fold enriched in p210BCR-ABL were defined as p210BCR-ABL 
enriched interactors.  We also defined those proteins displaying ratios that indicated 
greater than 1.5-fold but less than 1.8-fold difference between the cell types as trending 
towards an enrichment of interaction.  As a control we monitored the SILAC ratios of 
known endogenously biotinylated proteins commonly found in BioID experiments43 and 
those were not enriched in either cell type (Figure 3.2a).  We then examined the 
differential interactors within the subset of 90 proteins identified after filtering steps.  
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Many of the molecules identified to be enriched in their interactions with p190BCR-ABL are 
cytoskeletal proteins. Members of the Wiskott-Aldrich syndrome protein family, 
specifically, WASP, WAS/WASL-interacting protein family member 1 (Wipf1) and 2 
(Wipf2), and WAS Protein Family Member 2 (Wasf2) all displayed >1.8-fold increased 
association with p190BCR-ABL relative to p210BCR-ABL.  Interestingly, BCR-ABL has been 
previously shown to interact with the cytoskeleton and has been implicated in inducing 
cytoskeletal-related phenotypes, although these alterations were not assigned to a specific 
variant45–49. The differential interaction with Wipf1 identified through our quantitative 
mass spectrometry data was confirmed by immunoblot analysis of streptavidin enriched 
isolates from p190BCR-ABL, p210BCR-ABL and parental (as a negative control) cell lysates 
(Figure 3.2b).  Adaptor proteins, such as Nck1, Nck2, and intersectin 2, also known as 
SH3p18-Like WASP-Associated Protein (Itsn2), are not explicitly cytoskeletal but have 
been shown to mediate cytoskeleton signaling pathways, also displayed an increased 
interaction with p190BCR-ABL in our analysis.  Finally, signal-induced proliferation-
associated protein 1 (Sipa1) and signal-induced proliferation-associated 1-like protein 1 
(Sipa1l1), also modulators of the cytoskeleton, exhibited a modest preferential interaction 
with p190BCR-ABL.  Sipa1 has been previously shown to interact with BCR-ABL and 
displays co-localization to uropod actin structures of migrating cells, suggesting that 
BCR-ABL is likely found at these structures.50  Here, we show that these important 
cytoskeletal re-modeling factors preferentially interact with the p190BCR-ABL variant. 
In contrast to the findings for p190BCR-ABL, many of the proteins that displayed increased 
association with p210BCR-ABL (Figure 3.2c) are plasma membrane proximal proteins or 
display an increased activity at the plasma membrane.  For example, Ubash3b, a 
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membrane proximal adapter protein with phosphatase activity that targets Src and Syk 
family kinases and regulates plasma membrane bound receptor tyrosine kinases,51,52 was 
found to be 15-fold enriched in its interaction with p210BCR-ABL compared to p190BCR-ABL.  
Ubash3b is also a known interactor and negative regulator of Cbl51 and, intriguingly, Cbl 
and its homolog Casitas B-lineage lymphoma b (Cblb), were both enriched for p210BCR-
ABL interaction in our analyses (7-fold and 4-fold, respectively).  Cbl has previously been 
shown to form a complex with BCR-ABL and mediate the degradation of SHIP1 via 
polyubiquitination.53,54  Our data confirm the downregulation of SHIP1 upon expression 
of BCR-ABL, (compare inputs of both variant expressing cells to the parental line in 
Figure 2b).  Moreover, in addition to SHIP1, total protein levels of Cbl and Cblb are also 
downregulated compared to parental cells. Interestingly, the levels of SHIP1/Cbl/Cblb are 
downregulated in p190BCR-ABL to a greater extent than p210BCR-ABL suggesting that both 
forms are engaged in this complex but p190BCR-ABL might be mediating increased 
degradation of SHIP1 compared to p210BCR-ABL.  The preferential interaction of Cbl and 
SHIP1 with p210BCR-ABL along with assessment of their protein abundance was confirmed 
by immunoblotting streptavidin isolates and whole cell lysates (Figure 3.2b).  A 
combination of higher total protein levels of SHIP1 in p210BCR-ABL cells and the presence 
of the p210BCR-ABL enriched interaction of Ubash3b could also play an inhibitory role in 
the degradation SHIP1.  Ubash3b is a ubiquitin binding protein and could be binding to 
ubiquitinated SHIP1, thus attenuating its degradation.  Other membrane proximal 
proteins identified to be enriched in interaction with p210BCR-ABL include the phosphatase 
SHIP2 and adaptor proteins Crk and Shc1.   
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Finally, our data suggest that p190BCR-ABL and p210BCR-ABL engage with Stat proteins 
differently.  For example, Stat1 showed a 2-fold enrichment in p190BCR-ABL-specific 
interactions, which was confirmed by immunoblotting (Figure 3.2b).  In addition, both 
Stat5 and Stat3 were found to be enriched (2.5-fold and 1.5-fold) in p210BCR-ABL mediated 
interactions.  Importantly, previous studies have indicated that Stat5 is a direct substrate 
of BCR-ABL.55   
3.5 p190BCR-ABL and p210BCR-ABL interaction analysis in MPP cells 
In an effort to confirm our findings, we interrogated p190BCR-ABL and p210BCR-ABL 
interaction differences in an alternate cell type.   We chose an ex vivo expanded primary 
murine hematopoietic progenitor cell derived from early B cell factor 1 (Ebf1) null fetal 
livers.  These cells exhibit a “multi-potent progenitor” phenotype and have been shown to 
be an excellent model for hematopoiesis prior to B cell specification since these cells can 
be induced in culture to differentiate toward the B, T and myeloid lineage.35,36,56,57  The 
p190BCR-ABL and p210BCR-ABL interaction analysis in MPP cells is diagramed in 
Supplemental Figure 2a.  Interrogating the MPP cells expanded our experimentally 
derived BCR-ABL interactome and the overlap with the Ba/F3 experiment is shown in 
Figure 3.2d.  Many of the same molecules were identified in the interactome analysis in 
both cell types and these analyses also uncovered some potentially cell-type specific 
interactions (Figure 3.2d).  Importantly, many of the specific differential interactions 
observed in the Ba/F3 cells were also observed in these cells.  For example, the 
preferential interaction of Dok1, WASP, Wipf1, Stat1, and Nck1 with p190BCR-ABL found 
in the MPP cells was in agreement with the Ba/F3 experiment, although the enrichment 
for these molecules was not as pronounced as was observed in Ba/F3 cells, perhaps due 
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to cell-type specific differences or due to the sensitivity of the label-free quantitation used 
in MPP experiments.  In order to confirm these interactions, we measured Wipf1, Stat1, 
and Ubash3b levels by subjecting the streptavidin isolates to immunoblotting and these 
data highlighted a clear p190BCR-ABL skewed interaction in MPP cells (Figure 3.2e).  Cbl 
and Cblb, which had shown robust increased interactions with p210BCR-ABL relative to 
p190BCR-ABL in Ba/F3 cells, were found to also display specific differential interactions in 
the MPP experiment, although, again, with more modest enrichments (Figure 3.2e and 
Supplemental Table 2). As in the experiments in the Ba/F3 system, p210BCR-ABL 
expressing MPPs displayed increased interactions with SHIP1, Ubash3b, SHIP2, Stat5, 
and Shc1 relative to p190BCR-ABL.   
3.6 Global phosphorylation signatures of p190BCR-ABL and p210BCR-ABL in Ba/F3 cells 
It is possible that increased interaction of the p190BCR-ABL and p210BCR-ABL variants 
with a specific set of proteins leads to the increased phosphorylation of those targeted 
proteins to induce unique signaling through downstream pathways. To identify and 
quantify phosphotyrosine sites that are induced or altered in either p190BCR-ABL or 
p210BCR-ABL harboring cells, we employed a 3-state SILAC strategy.  Specifically, we 
isolated lysates from Ba/F3 cells harboring BirA-tagged versions of p190BCR-ABL and 
p210BCR-ABL (as used in the BioID experiments) and, as a control for basal 
phosphorylation levels, from Ba/F3 cells containing no exogenous protein. Not 
surprisingly, global phosphorylation was observed to be higher in cells ectopically 
expressing the constitutively active kinases, p190BCR-ABL and p210BCR-ABL relative to the 
parental cells.  This was observed when lysates were enriched for pTyr containing 
proteins by immunoprecipitation with a pTyr specific antibody (Figure 3.3a).  Three  
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Figure 3.3 Tyrosine phosphorylation analysis of BCR-ABL variants. (a) Tyrosine 
phosphorylated proteins were immunoprecipitated from whole cell lysates (WCL) of parental, 
p190BCR-ABL and p210BCR-ABL Ba/F3 cells using anti-phosphotyrosine antibody and probed with the 
same antibody as indicated.  (b) Relative abundance of normalized tyrosine phosphopeptides based 
on their SILAC ratios (log2 scale) in p190BCR-ABL and p210BCR-ABL expressing Ba/F3 cells.  Selected 
proteins are labeled by name and corresponding phosphosite.  (c) Validation of tyrosine 
phosphorylation by western blot analysis in Ba/F3 cells.  All antibodies used were phosphosite 
specific with the exception of Ubash3b (in which case anti-phosphotyrosine antibody was used for 
the IP).  Antibodies against the proteins were used to detect the overall protein expression in each 
case. (d) A list of notable tyrosine containing peptides hyperphosphorylated in either p190BCR-ABL 
or p210BCR-ABL Ba/F3 cells.  The sites are grouped into categories of protein function; guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), cytoskeletal, 
membrane associated proteins, adapters, and kinases/phosphatases. (e) Plot of SILAC ratio values 
of MPP the p190BCR-ABL/p210BCR-ABL versus Ba/F3 the p190BCR-ABL/p210BCR-ABL.  Selected proteins 
are labeled by name and corresponding phosphosite. 
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technical replicates of pTyr enrichments were subjected to LC-MS/MS and subsequent 
analyses yielded quantitation of 1,568 pTyr sites on 965 proteins, 746 sites of which were 
sampled in all three replicates.  We measured phosphorylation ratios by calculating the 
median of replicate SILAC ratio p190BCR-ABL/p210BCR-ABL values of sites (all SILAC ratios 
are plotted in Figure 3.3b and all data is provided in Supplemental Table 3).  
Phosphosites displaying ratio values greater than 2-fold enriched in p190BCR-ABL were 
defined as p190BCR-ABL hyperphosphorylated, while values with 2-fold enriched in 
p210BCR-ABL were defined as p210BCR-ABL hyperphosphorylated.  We also define those sites 
displaying ratios that indicate greater than 1.5-fold but less that 2-fold difference between 
the cell types as trending toward hyperphosphorylation.  For a select number of 
phosphorylation sites, the mass spectrometry results were confirmed by immunoblotting 
with tyrosine phosphorylation specific antibodies (Figure 3.3c).    
3.7 Cytoskeleton proteins hyperphosphorylated in p190BCR-ABL expressing cells 
Strikingly, in very strong agreement with our analysis of p190BCR-ABL-skewed 
protein-protein interactions, we identified many sites on cytoskeletal proteins and 
cytoskeletal signal transduction pathway members to be hyperphosphorylated in response 
to p190BCR-ABL expression (Figure 3.3d). The hyperphosphorylation of the Wiskott-
Aldrich syndrome family member proteins WASP, its homolog Neural Wiskott-Aldrich 
syndrome protein (Wasl or N-WASP), and their interacting proteins Wipf1/2 are of 
particular interest as we also observed WASP and Wifp1 to be enriched in p190BCR-ABL 
interaction.  This combination of interaction and hyperphosphorylation not only 
implicates Wiskott-Aldrich syndrome family members as direct substrates of p190BCR-ABL 
but also further suggests that cytoskeletal pathways are being activated differently in 
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p190BCR-ABL expressing cells compare to p210BCR-ABL, as these proteins are potent effectors 
of these pathways.58  The specific function of the sites on the Wiskott-Aldrich syndrome 
family members observed to be p190BCR-ABL hyperphosphorylated further support the 
activation of this pathway.  For example, sites Tyr293 and Tyr253 on WASP and N-
WASP, respectively, are essential for the activation of both molecules.58 WASP-Tyr293 
hyperphosphorylation was confirmed by immunoblotting with a phospho-specific 
antibody and shown in Figure 3c.  Activated N-WASP is essential for actin assembly and, 
via recruitment of Nck1 and Grb2, promotes actin based movements.59  In agreement 
with the previous finding, we observed hyperphosphorylation of many sites on Nck1, 
Nck2, and Grb2 in p190BCR-ABL expressing cells.  Both Nck1 and Nck2 were also 
identified as preferentially interacting with p190BCR-ABL, suggesting that this BCR-ABL 
variant is co-located with all these proteins.  The protein complex of Nck1/Grb2/Wiskott-
Aldrich syndrome family members has been shown to be mediated by Abl-dependent 
phosphorylation of Tyr361 on Dok1.  Phosphorylation of Dok1 recruits Nck1 to interact 
with Wiskott-Aldrich syndrome family members which initiates actin polymerization and 
filopodia in mouse embryonic fibroblasts.60  Remarkably, we identified 9 tyrosine sites, 
including Tyr361, on Dok1 that are hyperphosphorylated in p190BCR-ABL expressing cells, 
further implicating enriched association of p190BCR-ABL with the cytoskeleton compared to 
p210BCR-ABL.  Importantly, Dok1 trended towards an increase of p190BCR-ABL interaction in 
the interactome data.  Taken together, the combination of preferential interaction and 
hyperphosphorylation of key residues of Wiskott-Aldrich syndrome family members, 
Nck1/2, Grb2, and Dok1 suggest that p190BCR-ABL is profoundly influencing the 
cytoskeleton.    
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3.8 Phosphorylation signatures of p210BCR-ABL expressing cells 
p210BCR-ABL displayed preferential protein-protein interactions with some 
important membrane-proximal proteins, including Ubash3b, SHIP2, Cbl, Cblb, and 
SHIP1. In agreement with this p190BCR-ABL/p210BCR-ABL differential interaction, we also 
observed differential phosphorylation signatures indicating that the variants are exerting 
increased influence on these proteins and pathways.  In general, increased p210BCR-ABL 
interaction was coupled with increased phosphorylation.  For example, a novel 
phosphotyrosine site on Ubash3b (Tyr9) was observed to be hyperphosphorylated in 
p210BCR-ABL cells.  To validate this novel site, we used an anti-pTyr antibody to isolate all 
pTyr proteins in the cells, and followed this immunoprecipitation with immunoblotting 
for Ubash3b proteins (Figure 3.3c).  A direct comparison of total protein versus pTyr 
enriched, shows that Ubash3b is indeed more highly phosphorylated in p210BCR-ABL 
expressing cells (compare total protein with anti-pTyr enriched) leading us to conclude 
that Ubash3b is more active in p210BCR-ABL expressing cells.  Other examples of 
concurrent p210BCR-ABL interaction and hyperphosphorylation were found in SHIP1 and 
SHIP2.  As for SHIP1 phosphorylation we observed p210BCR-ABL hyperphosphorylation 
on the sites Tyr917 and Tyr1020. The SHIP1 sites Tyr917 and Tyr1020 are interesting 
because Dok1/Shc1 compete for binding at Tyr1020.54,61,62  This might be noteworthy 
because, in our BioID analysis, Shc1 is favored by p210BCR-ABL and Dok1 by p190BCR-ABL, 
implicating some interesting differential interplay between Shc1/Dok1/SHIP1 with 
respect to the two BCR-ABL variants.  SHIP2 showed a robust increase in 
phosphorylation on Tyr1161 (2.4-fold enrichment over p190BCR-ABL expressing cells) and 
with additional phosphosites Tyr986, Tyr835, and Tyr662 all trending toward enrichment 
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(>1.5-fold) in p210BCR-ABL expressing cells.  The site Tyr1136 (Tyr1135 in human) on 
SHIP2 showed a reciprocal relationship between interaction and phosphorylation as it 
was observed to be hyperphosphorylated in p190BCR-ABL expressing cells.  
Phosphorylation of this site has previously been shown to translocate SHIP2 to focal 
adhesions63 which further implicates a connection of p190BCR-ABL to the cytoskeleton and 
suggests that the two variants use SHIP2 in different ways to promote their unique 
signaling programs.  Cbl and Cblb represent another example against the general trend of 
increased interaction leading to increased phosphorylation. Specifically, Cbl and Cblb 
display a shared phosphopeptide that is hyperphosphorylated in p190BCR-ABL cells (where 
the interaction is less). These sites, Tyr369/363 (Tyr371/363 in human) increase the 
ubiquitin ligase activity of Cbl when phosphorylated.64  This observation has particularly 
intriguing implications for poly-ubiquitination/degradation of SHIP1 by Cbl/BCR-ABL 
and could explain in part why SHIP1 is less abundant in p190BCR-ABL expressing cells due 
to increased degradation.  
The rhoGEF domain in p210BCR-ABL has been shown to be constitutively activated and 
mutations that disrupt the activity of this domain decrease the transforming potential of 
the oncogene.65 We wanted to investigate if any G-protein signaling pathway related 
proteins were differentially regulated by phosphorylation, which could identify those 
potentially working in concert with p210BCR-ABL to produce specific rhoGEF pathway 
signaling programs.  We did observe many tyrosine sites on guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs) that were hyperphosphorylated in 
p210BCR-ABL cells (Figure 3.3d).  For example, Arf-GAP with a rho-GAP domain, ANK 
repeat and PH domain-containing protein 1 and 3 (Arap1/CENTD2 and 
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Arap3/CENTD3), Arf-GAP with coiled-coil, ANK repeat and PH domain-containing 
protein 1 (Acap1), rho guanine nucleotide exchange factor 6 (Arhgef6), rho GDP-
dissociation inhibitor 1 (Arhgdia), and proto-oncogene Vav 1 (Vav1) are all 
hyperphosphorylated.   
3.9 Differential regulation of Stat proteins 
Previous work using immunoprecipitation and immunoblotting in the Ba/F3 
system has revealed that Stat family members are differentially regulated by p190BCR-ABL 
and p210BCR-ABL12,21.  In one study, Stat1 and Stat6 were found to show higher 
phosphorylation in p190BCR-ABL expressing Ba/F3 cells, while Stat5 phosphorylation was 
higher in p210BCR-ABL expressing Ba/F3 cells and Stat3 exhibited no change in 
phosphorylation levels.   To confirm and extend this observation, which was limited by 
available antibodies and only detected overall levels of phosphorylation, we interrogated 
our differential pTyr phosphorylation data to determine differences at specific sites of 
phosphorylation induced by the BCR-ABL variants (summarized in Table 1).  We 
identified a total of nine sites on Stat family proteins (Stat1, Stat2, Stat3, Stat5, and 
Stat6), six of which displayed hyperphosphorylation in either p190BCR-ABL or p210BCR-ABL 
expressing cells.  We confirmed several of these sites, identified in our mass 
spectrometry data, by immunoblotting extracts from p190BCR-ABL or p210BCR-ABL 
expressing cells using commercially available phosphorylation site-specific antibodies 
(Figure 3.3c).  These data confirm that sites Tyr701 in Stat1 and Tyr641 in Stat6 are 
hyperphosphorylated preferentially in p190BCR-ABL cells.  Phosphorylation of Tyr701 and 
Tyr641, located just outside the SH2 domain, is required for dimerization, nuclear 
translocation, and DNA binding activity of both Stat1 and Stat6.66,67  A similar site 
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Tyr694, as well as neighboring sites Tyr668 and Tyr682/3 in the SH2 domain, in Stat5a/b 
showed no change by mass spectrometry or immunoblotting.  However, in p210BCR-ABL 
expressing cells, we identified an increase of phosphorylation at Tyr90 and Tyr114, 
which is located near the DNA binding domain of Stat5a/b. Although the exact role of 
phosphorylation at Tyr90 and Tyr114 is not well understood, these tyrosine residues do 
reside within the tetramerization domain which is important for protein-protein 
interactions and is involved in altering local chromatin structures upon DNA binding.68 
Stat3 also had an N-terminal (Tyr45) phosphosite hyperphosphorylated in p210BCR-ABL 
cells similar to the pattern observed in Stat5. These data support that the Stat proteins are 
differentially engaged by the BCR-ABL variants, and we identify the differential and 
specific residues through which these proteins are inducing this pathway. 
3.10 Correlation of global phosphorylation signatures between p190BCR-ABL/p210BCR-
ABL in the MPP and Ba/F3 cells:  
Next, we chose to interrogate phosphorylation signatures in another cellular 
background as a means of biological validation.  Just as we did with our interactome 
analysis, we leveraged BCR-ABL variant expressing MPP cells.  Experimental workflow 
for phosphorylation analysis in MPP cells is shown in Supplemental Figure 2b.  The 
correlation of p190BCR-ABL/p210BCR-ABL phosphorylation changes in Ba/F3 and MPP cells 
is plotted in Figure 3e and all MPP phosphorylation data are listed in Supplemental Table 
4.  Molecules with sites that showed the same trend of phosphorylation in both cell types 
and were also enriched among p210BCR-ABL interactors were Ubash3b (Tyr8), SHIP1 
(Tyr918/Y886), Crk (Tyr108), and Shc1 (Tyr423).  We also observed the 
hyperphosphorylation of the ubiquitin ligase activating site Tyr369/363 (discussed above) 
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on Cbl/Cblb in MPP p190BCR-ABL cells.  As for phosphorylation signatures of proteins 
enriched for p190BCR-ABL interaction, we observed similar hyperphosphorylation of 
WASP, N-WASP, Wipf2, Itsn2, Dok1, and Nck1 in MPP as Ba/F3 cells further 
implicating p190BCR-ABL specificity for these molecules.   
In addition to directly phosphorylating interacting proteins, BCR-ABL induces 
downstream signaling pathways as well. Many downstream tyrosine kinases were 
observed in both Ba/F3 and MPP cells to be differentially phosphorylated between 
p190BCR-ABL and p210BCR-ABL, which suggests that the two variants could be collaborating 
with other kinases to induce unique signaling programs.  Sites on kinases such as tyrosine 
protein kinase Lyn (Lyn), tyrosine protein kinase Csk (Csk), tyrosine protein kinase Tec 
(Tec), tyrosine protein kinase Syk (Syk), and tyrosine kinase non-receptor 2 (Tnk2) were 
observed to be differentially phosphorylated in p190BCR-ABL and p210BCR-ABL cells (Figure 
3.3e).  Tyr265, located near the N-terminal side of the kinase domain in Lyn, was 
hyperphosphorylated in p210BCR-ABL cells in both cellular backgrounds and Tyr193/194 
located within in the SH2 domain was conversely hyperphosphorylated in p190BCR-ABL 
cells.  The p190BCR-ABL hyperphosphorylation at residues Tyr64 and Tyr18 of Csk, a 
regulator of Src family kinases, could indicate increased activation.   
3.11 The integration of interactome and phosphorylation data highlights differently 
regulated molecules by p190BCR-ABL and p210BCR-ABL 
To better characterize the findings from both analyses, we integrated the 
differential interactome and differential phosphoproteome data (Figure 3.4).  Common 
protein interactors represent molecules that display similar association with p190BCR-ABL 
and p210BCR-ABL, as determined by BioID and SILAC-based mass spectrometry analysis.  
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These interactions likely represent general BCR-ABL interactions, since many of these 
same proteins are hyperphosphorylated in both BCR-ABL variant expressing cells, as 
compared to cells not expressing any BCR-ABL protein (Supplemental Table 2).  
Strikingly, overlaying the differential interactome and phosphoproteome data reveals a 
general agreement between increased interaction and increased phosphorylation 
demonstrating the power of this approach (Figure 3.4).  For instance, in p210BCR-ABL cells, 
SHIP2, SHIP1, Ubash3b, Pik3ap1 and Crk have concurrent enrichment for interaction 
and phosphorylation.  Similarly, in p190BCR-ABL cells, WASP, Wipf1, Nck1, Dok1, Itsn2 
and DAB2 interacting protein (Dab2ip) have concurrent enrichment for interaction and 
phosphorylation.  The large majority of the interactors that are not enriched for either 
variant have near equal phosphorylation signatures.  An interesting group of molecules 
are those that appear to be equal interactors yet have differential p190BCR-ABL/p210BCR-ABL 
phosphorylation signatures, such as the kinase leucine rich repeat kinase 1 (Lrrk1) and 
the focal adhesion localized protein Zyxin (Zyx).  Another interesting group of molecules 
are those that show modest interaction preference to one variant and have increased 
phosphorylation in the same direction.  Examples include the Arap1 (a GEF protein 
discussed above), the non-receptor tyrosine kinase Peak1, and cytokine dependent 
hematopoietic cell linker (Clnk) which is involved in the regulation of the B cell antigen 
receptor (Figure 3.4).  Interestingly, in the MPP BioID experiment Clnk was found to be 
2-fold enriched in p190BCR-ABL interaction which highlights the utility of combining both 
interaction and phosphorylation data to identify differentially regulated proteins.    
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Figure 3.4 Integrative analysis of p190BCR-ABL and p210BCR-ABL phosphorylation and 
interactome signatures. Interacting proteins of p190BCR-ABL and p210BCR-ABL are represented by 
circles and are place from left to right based on their SILAC ratios in the interactome analysis.  A 
three-color gradient represents the degree of enrichment, with blue representing an enrichment with 
p210BCR-ABL interactions, yellow representing an enrichment with p190BCR-ABL, and green 
representing equal interactions between the two variants.  Circles are scaled based on the number 
of peptide spectral matches (PSMs) in the interactome experiment, which is suggestive of the 
relative strength of the interactions.  Arrows point toward boxes containing tyrosine sites 
corresponding to proteins found in interaction analysis and the phosphorylation signature observed, 
with respect to p190BCR-ABL /p210BCR-ABL.  Blue dots are used to denote at least greater than 2-fold 
increase in phosphorylation enrichment in p210BCR-ABL cells while yellow dots represents at least 
greater than 2-fold increase in phosphorylation in p190BCR-ABL cells.  Lighter shades of blue and 
yellow dots indicate greater than 1.5-fold enriched in each cell type.  Green dots signify no 
phosphorylation change between p190BCR-ABL or p210BCR-ABL cells. 
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3.12 In a multipotent background p190BCR-ABL and p210BCR-ABL regulate total 
protein levels of important hematopoietic drivers differently 
Differential signaling programs employed by either p190BCR-ABL or p210BCR-ABL 
likely lead to differences in the regulation of the total proteome.  In an effort to identify 
proteins whose abundance was differentially regulated as a result of p190BCR-ABL or  
p210BCR-ABL expression, we examined the total proteome data from Ba/F3 and MPP 
experiments (data is listed in Supplemental Tables 5 and 6, respectively).  Notably, in the 
MPP experiment, we observed a number of important hematopoietic 
development/leukemia related proteins that were differentially expressed between 
p190BCR-ABL and p210BCR-ABL.  In p190BCR-ABL MPP cells, many hematopoietic 
developmentally regulated cell surface markers were upregulated in comparison to 
p210BCR-ABL cells.  These included CD14, CD81, CD9, CD166 and CD44.  An important 
driver of B cell lymphopoiesis, transcription factor E2-alpha (E2A/Tcf3), was 
upregulated in p190BCR-ABL MPP cells.  E2A is essential for initiating differentiation of 
uncommitted hematopoietic progenitors to pro-B cells and when translocated with the 
PBX1 gene is a potent driver of a subset of ALL.69  Notable proteins upregulated in 
p210BCR-ABL MPP cells are listed in Table 2, which includes the transcription factors AT-
rich interactive domain-containing protein 3A (Arid3a) and runt related transcription 
factors 1 and 3 (Runx1 and Runx3, respectively).  Aberrant Arid3a expression levels 
have been shown to alter normal hematopoiesis, as overexpression of Arid3a results in 
inhibition of maturation of myeloid lineages while downregulation of Arid3a results in 
decreased B cell production.70  Both Runx1 and Runx3 have important roles in 
hematopoiesis and myeloid leukemia.71,72  Myeloperoxidase (MPO), a common 
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diagnostic marker differentiating myeloid from lymphoid leukemia was enriched in 
p210BCR-ABL MPP cells.  Cell surface markers CD48, CD82 and the hematopoietic stem 













BioSITe: A METHOD FOR DIRECT DETECTION 
AND QUANTITIATION OF SITE -SPECIFIC 
BIOTINYLATION   
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The following work was published in the Journal of Proteome Research and all reference 
to supplemental data/figures can be found at the Journal of Proteome Research website 
with the following this citation73.   
4.1 Proximity dependent labeling technologies do not detect biotinylated proteins 
To improve the biotinylated peptide detection issue, we have developed a strategy 
designated Biotinylation Site Identification Technology (BioSITe), which is based on the 
use of anti-biotin antibodies to directly capture and identify biotinylated peptides in a 
single LC-MS/MS run. We show that detection of biotinylated peptides greatly increases 
the confidence of candidate protein identification in proximity-dependent biotinylation 
methods. By providing the site of biotinylation on proteins labeled in these methods, this 
approach also offers a new level of information about the structural aspects of PPIs and 
protein topology. Finally, we describe a simple approach for quantitative BioSITe 
experiments through the use of isotopically labeled biotin obviating the use of metabolic 
labeling based quantitative strategies such as SILAC33.  
 
4.2 Detection of biotinylated peptides using BioSITe 
Proteins that are biotinylated by proximity-dependent biotinylation methods 
(Figure 1A) are generally captured by streptavidin-conjugated beads followed by on-bead 
digestion (hereafter referred to as the conventional method) (Figure 4.1B top). We 
reasoned that the strong affinity between biotin and streptavidin (Kd= ~10-15) 74 is a 
critical factor that limits elution and subsequent detection of biotinylated peptides. To 
overcome this, we decided to use a capture reagent with a lower affinity, i.e. a biotin-
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specific antibody, which would allow for dissociation of biotin and identification of 
biotinylated sites (Figure 4.1B bottom). To evaluate the potential of BioSITe in 
improving analysis of proximity labeling interactome studies, we leveraged our 
previously characterized Ba/F3 cell system that was engineered to stably express the 
BCR-ABL oncogene (p190 variant) cloned in-frame with BirA* 75. Based on our testing 
of a panel of commercially available antibodies against biotin, we chose two polyclonal 
antibodies (from Abcam and Bethyl Laboratories) that yielded high signal intensities 
from immunoprecipitation of biotinylated proteins followed by Western blotting of whole 
cell lysates of BirA*-p190 (Supplementary Figure 1A). Tryptic peptides generated from 
these samples were separately immunoprecipitated with each antibody and analyzed by 
LC-MS/MS (see Methods and Materials for details regarding the enrichment and MS 
analysis). Peptides containing biotinylated lysines were readily detected including a 
biotinylated peptide of SHC1 adapter protein 1 (SHC1), a direct binding partner of BCR-
ABL, and its spectrum is shown in Figure 1C (9, 10). Lysine biotinylation was evidenced 
by MS/MS spectrum with three signature ion peaks as well as a series of fragmentation 
ions harboring biotin. The signature ions, m/z 227, m/z 310 and m/z 314, correspond to 





Figure 4.1 An overview of BioSITe. (A) A schematic of biotinylation labeling techniques 
commonly used to identify protein-protein interactions in vivo. A bait protein (green) fused to an 
engineered biotinylation enzyme (APEX2 or BioID, purple) biotinylates proteins in the proximity 
of the enzymes. Biotinylation - red circles with “B”, interacting proteins, brown/black, labeling 
radius, blue. (B) In conventional methods for candidate protein identification, biotinylated proteins 
are generally captured by streptavidin (green) conjugated to beads under denaturing conditions. 
Proteins bound to the beads are subsequently digested generating non-biotinylated peptides (brown 
and grey), which readily elute from the beads and can be identified by LC-MS/MS, and biotinylated 
peptides (cyan) that remain tightly bound to the beads. In BioSITe, proteins are digested prior to 
enrichment and biotinylated peptides are captured using by anti-biotin antibodies coupled to beads. 
(C) MS/MS spectra of SHC-transforming protein 1 (SHC1) biotinylated peptide detected by LC-
MS/MS. Fragment ions adjacent to the biotin modification that confirm the site of biotinylation are 
indicated in red.  (D) Lack of overlap of biotinylated peptides identified from BirA*-BCR-ABL 
detected by the conventional method or BioSITe. (E) Overlap of biotinylated proteins identified by 
BioSITe (green) and by the conventional method of on-bead digestion (purple).  
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an immonium ion harboring biotin with a loss of NH3 and an immonium ion harboring 
biotin, respectively (4, 5). Since we observed a partially overlapping pattern in terms of 
site identification, we used both antibodies together in subsequent BioSITe experiments 
(Supplemental Table 1) (Supplementary Figure 1B). 
We next sought to compare the performance of BioSITe with other methods available for 
biotinylated protein or peptide capture. We analyzed triplicate samples from (i) whole 
protein capture followed by on-bead digestion; (ii) biotinylated peptides eluted from 
beads subsequent to on-bead digestion; (iii) neutravidin-based biotinylated peptide 
capture method (DiDBiT); and, (iv) whole protein capture with anti-biotin antibodies 
followed by elution and in-solution digestion. MS data from BioSITe experiments 
identified 3,403 biotinylated peptides corresponding to 1,193 proteins (Supplemental 
Table 2). On-bead digestion identified 11 biotinylated peptides (Supplemental Table 3), 
with no overlap of those biotinylated peptide identified by BioSITe (Figure 4.1D). 
Similarly, elution after on-bead digestion identified 55 biotinylated peptides 
(Supplementary Figure 1C and Supplemental Table 4), DiDBiT detected 924 biotinylated 
peptides (Supplementary Figure 1D and Supplemental Table 5) and whole protein 
capture with anti-biotin antibodies followed by elution and in-solution digestion 
identified only 44 biotinylated peptides (Date not shown). Importantly, BioSITe led to 
identification of the largest number of biotinylated peptides of all methods tested in our 
study. Based on these findings, we conclude that ease of dissociating biotinylated 
peptides from anti-biotin antibodies combined with the peptide level enrichment is 
responsible for a higher number of identification using BioSITe. However, given that 
DiDBiT and BioSITe outperform both whole protein enrichment methods (21-85 and 77-
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309 fold increase in biotinylated peptide identification, respectively), we conclude that 
the peptide level enrichment step provides the greatest increase in identification while the 
choice of capture reagent (avidin analog or antibody) provides an additional ~4-fold 
increase in the number of biotinylated peptides that are identified. 
When we compared the list of proteins whose biotinylated sites were detected by 
BioSITe with proteins identified from conventional on-bead digestion, we found a 
substantial overlap (718 proteins) which included well-documented interacting proteins 
such as SHC1, ABL interactor 1 (ABI1), ubiquitin-associated and SH3 domain-
containing protein B (UBASH3B), phosphatidylinositol 3,4,5-trisphosphate 5-
phosphatase 1 (SHIP1), inositol polyphosphate phosphatase like 1 (SHIP2) and growth 
factor receptor-bound protein 2 (GRB2) (Figure 4.1E) 75,76. There were 467 biotinylated 
proteins identified only by BioSITe, representing a subset of biotinylated proteins that 
were missed by conventional on-bead digestion (Figure 4.1E). Importantly, 23% 
(110/467) of these proteins have more than 2 sites of biotinylation; however, the 
majority, 77% (359/467), of these proteins are represented by only 1 site of biotinylation 
indicating that these could represent low abundant proteins or transient interactions only 
observable by BioSITe. In addition, we observed that 807 proteins were uniquely 
identified by the conventional method and we hypothesize that many of these represent 
non-specifically bound proteins (46% (378/807) are represented by ≤2 PSMs) 
(Supplemental Table 2).  
4.3 Mapping of biotinylation sites in proteins 
To study the pattern of protein biotinylation and to determine if any interesting 
features could be revealed by the degree of biotinylation and the location of biotinylation 
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sites, we generated a curated list of core interactors of BCR-ABL. We then grouped these 
proteins according to the proportion of lysines that were detected to be biotinylated 
(Figure 4.2A). Among the proteins with the greatest degree of biotinylation, we found 
that established direct BCR-ABL interactors such as GRB2 77,78 , GRB2 associated 
binding protein (GAB2) 79,80 and SHC1 81 contained >23% of lysines that were 
biotinylated. The bait protein, BCR-ABL, exhibited even higher biotinylation as 75 of 95 
lysine residues were biotin-modified, whereas other proteins known to interact with 
BCR-ABL via an adaptor subunit, e.g. PIK3CA/B, exhibited a lower extent of 
biotinylation (3%). Thus, we hypothesize that a high degree of biotinylation could reflect 
proximity and high residence time between BCR-ABL and its interactors and/or 
substrates. Mapping of biotinylated lysines onto the structures of corresponding proteins 
revealed that the majority of biotinylated lysines were in regions with low secondary 
structures (i.e. located within N- or C-termini or interdomain linkers outside of folded 
domains). As expected in this case, a majority of biotinylated sites were positioned near 
known functional domains involved in protein-protein interactions with BCR-ABL such 
as src homology 2 (SH2) domain, phosphotyrosine binding (PTB) domain and src 
homology 3 (SH3) domain (Figure 4.2B). For instance, GRB2, which binds BCR-ABL 
via its SH2 domain is highly biotinylated in both of its SH3 domains that are located 
adjacent to the SH2 domain, while the adapter molecule, CRK proto-oncogene adaptor 
protein (CRK), is additionally biotinylated on the SH2 domain itself (Figure 4.2B). Two 
biotinylated lysine residues (K689, K696) of signal transducer and activator of 
transcription 5A (STAT5A), a prominent substrate of BCR-ABL, are also found adjacent 




Figure 4.2 Mapping of biotinylation sites. (A) Biotinylated proteins identified by BioSITe were 
grouped by the degree of biotinylation. (B) Three dimensional models of representative proteins 
identified in the study. GRB2, and CRK are homology models based on their human homologues 
(PDB ID 1GRI and 2EYZ, respectively) while the structure of STAT5A was taken from PDB ID 
1Y1U. The other domain structures from each protein were modeled using their human homologs 
from PDB. Lysine residues that are biotinylated upon interaction with BirA*-BCR-ABL are 
highlighted as red sticks and labeled with their position. The biotinylated lysines are in colored in 
red and the functional domains are indicated (CC: coiled coil, ROC: ras of complex proteins PH: 
pleckstrin homology, SH3: Src-homology 3, SH2: Src-homology 2, PID: phosphotyrosine 
interaction domain, DBD: DNA-binding domain). 
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phosphorylation of STAT5A by BCR-ABL 82,83. Taken together, our observations 
suggest that the site level information generated by BioSITe could be potentially useful 
for gaining spatial information on the architecture of protein complexes. 
4.4 Application of BioSITe for quantitative proteomics 
Given the utility of identifying site-specific biotinylation sites, we wished to adopt a 
quantitative approach that would allow us to investigate relative abundance of 
biotinylated peptides under different biological conditions. Traditionally, accurate 
relative quantitation approaches have relied upon SILAC which is based on metabolic 
incorporation of stable isotope containing amino acids into proteins in living cells 33. 
Here, instead of using heavy amino acids, we decided to use heavy biotin in the BioID 
experiment that would serve the same purpose. Again, we used our previously established 
system for interrogating the differential interactomes of two variants of BCR-ABL 
oncogene 75. The p190 and p210 versions of BCR-ABL differ from each other only by 
the presence or absence of DH and PH domains but have distinct phenotypes in humans. 
We previously tagged both variants with BirA* (hereafter referred to as BirA*-p190 and 
BirA*-p210) 75 and used SILAC-based quantitation to characterize their differential 
interactomes 75,76. We repeated the experiment by culturing the cells overnight in “heavy 
(2H4)” or “light (H4)” biotin (Figure 4.3A). LC-MS/MS analysis of mixed cell lysates 
from BirA*-p190 and BirA*-210 cells using BioSITe revealed the expected mass 
differences at the MS as well as MS/MS levels on biotinylated peptides (Supplementary 
Figure 2A). As expected, the biotinylation sites from the DH and PH domain of BCR-
ABL p210 were highly enriched in BirA*-p210 harboring cells (Figure 4.3B, 
Supplemental Table 6). To compare this BioSITe experiment with labeled biotin with our 
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previous SILAC-based BioID study, we averaged all biotinylation site ratios in the 
BioSITe data for specific proteins. We found many differential interactors determined by 
our previous studies to be relevant for BCR-ABL p190 and p210 specific signaling 
pathways - these included the p210 enriched interactors of SHIP1, SHIP2, CBL, 
UBASH3b (Supplementary Figure 4.2B) and the p190 enriched interactors of Wiskott-
Aldrich Syndrome protein (WAS), and WAS/WASL-interacting protein family member 1 
(Wipf1) 75,76. Our quantitative BioSITe analysis also led to identification of potentially 
novel interactors that preferentially interacted either with p190 (e.g. SRSF protein kinase 
2 (SRPK2) and BRCA1 associated protein (BRAP)) or with p210 (e.g. C-terminal src 
kinase (CSK) and PDGFA associated protein 1 (PDAP1) (Figure 4.3B). Interestingly, we 
did not previously identify CSK as a p210-specific interactor although it was found to be 
hyperphosphorylated in cells expressing p210. Thus, the preferential interaction between 
CSK and p210 BCR-ABL, which observed by quantitative BioSITe, further implicate its 
role in p210 specific signaling pathways 75,76.  
Our quantitative BioSITe approach has potential advantages over traditional SILAC for 
proximity based labelling methods. While SILAC requires multiple passages to ensure 
complete metabolic labeling, which has its limitations with difficult to culture and slowly 
dividing cells, the addition of heavy labeled biotin can be completed with an overnight 
incubation in the setting of BioID. Using heavy biotin-phenol in the APEX system 
coupled with BioSITe is another potential of the method as APEX requires a very short 
labeling time (<1 minute) 3,84.  
4.5 Applying BioSITe to the APEX system  
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Figure 4.3 Overview of quantitative BioSITe. (A) Experimental workflow for differential 
interactome analysis of BirA*-p210 and BirA*-p190. Ba/F3 cells expressing BirA*-p210 and 
BirA*-p190 were incubated overnight with media containing light (green) or heavy biotin 
containing four deuterium atoms (red), respectively. Equal amounts of cell lysates from each 
condition were mixed and digested into peptides. Biotinylated peptides were enriched using 
BioSITe and analyzed by LC-MS/MS. (B) A plot of relative abundance of the biotinylated sites 
between BirA*-p210 and BirA*-p190. Identified biotinylated sites and the corresponding proteins 
are plotted according to their log2 intensity ratios (BirA*-p190/BirA*-p210). 
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To demonstrate the broad applicability of BioSITe, we applied our method to 
APEX, another proximity-dependent biotinylation method 4. We chose an established 
system of mapping the mitochondrial subcellular proteome in which we expressed 
APEX2-fused to signal sequences targeting it to either the intermembrane space in the 
mitochondria (IMS -APEX2) or the cytoplasm (NES-APEX2) in HEK293T cells (Figure 
4.4A)4. We carried out BioSITe experiments in triplicate for both IMS-APEX2 and NES-
APEX2 and mass spectrometry analysis confirmed enrichment of biotin-phenol modified 
peptides (Figure 4.4B). Peptides containing biotin-phenol modified tyrosines were readily 
detected by LC-MS/MS analysis in both experiments. Biotin-phenol modified tyrosines 
were confirmed by MS/MS spectrum with three signature ion peaks as well as a series of 
fragmentation ions harboring biotin. The signature ions, 227.08, 480.19 and 497.22, 
correspond to fragmented biotin, biotin-phenol modified tyrosine immonium ion with 
loss of NH3, and biotin-phenol modified tyrosine immonium ion, respectively (Figure 
4B) 3,84. 
BioSITe identified a total of 1,454 biotin-phenol modified peptides derived from 656 
proteins from IMS-APEX2 labeled lysates (Supplemental Table 7) and 1,924 biotin-
phenol modified peptides derived from 786 proteins from NES-APEX2 labeled lysates 
(Supplemental Table 8). After filtering out modified peptides common to both NES-
APEX2 and IMS-APEX2 samples, we identified 384 BPMPs representing 244 proteins 
uniquely identified by IMS-APEX2 (Figure 4.4C) When we compared our data with a 
previously published study using the same system in which 135 IMS proteins were 
identified 4, we observed that 62 proteins were identified by both methods. Of the 182 
proteins that were only identified by the BioSITe method, 74 proteins are already 
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annotated in MitoCarta, a mitochondrial protein database (Figure 4.4C) 85 suggesting that 
these proteins were likely bona fide proteins that were missed by the previous study. 
Further, BioSITe identified 345 biotinylated sites while the previous study found 80 sites 
of which 45 biotinylated peptides were identified by both methods and the large majority 
were unique to the BioSITe method (Figure 4.4D).  
Recently, a method based on desthiobiotin-phenol, a synthetic biotin-phenol derivative, 
has been applied to the APEX system, which takes advantage of weaker affinity of 
desthiobiotin-phenol to streptavidin 84. In this study, desthiobiotin-phenol-containing 
peptides were enriched and used to define the IMS proteome. When we compared 
proteins and peptides identified by all three methods (in-gel digestion-based methods by 
Hung et al., desthiobiotin-phenol-based study by Lee et al. and BioSITe), BioSITe 
yielded more labeled peptides and proteins (Supplementary Figure 3A and 3B). We have 
noticed that there are many proteins and peptides that are uniquely identified by each 
method suggesting perhaps that mitochondrial proteome is still insufficiently cataloged, 
issues with sampling, inherent biases of each method or a combination of these factors 
(Supplementary Figure 3A and 3B). As an additional caveat, we cannot rule out the 
possibility that each dataset includes false positives owing to porous mitochondrial outer 
membrane, which could itself lead to labeling of cytosolic proteins 4. 
4.6 Biotinylation site-dependent topology prediction 
A promising attribute of site-specific biotinylation data in the context of subcellular 
proteome mapping is the ability to infer topology of proteins with transmembrane 





Figure 4.4 Application of BioSITe to the APEX system and biotin-based click chemistry (A) 
APEX2 constructs targeted to either the mitochondrial intermembrane space (IMS-APEX2) or 
cytoplasm (NES-APEX2) were expressed in HEK293T cells. APEX2 leads to labeling of proximal 
proteins in the intermembrane space or the cytoplasm with biotin-phenol (B, red). (OMM; outer 
mitochondrial membrane, IMM: inner mitochondrial membrane). (B) MS/MS spectrum of a biotin-
phenol labeled peptide corresponding to COX assembly mitochondrial protein 2 homolog (CMC2). 
Peaks labeled in red indicate fragment ions series with or without mass shift by biotin modification. 
All peaks containing biotin are label with “Bio.” (C) Overlap of proteins identified by BioSITe 
(yellow) with that from a previous study identifying IMS proteins using a conventional in-gel 
digestion method (Hung et al. blue). The proteins unique to the BioSITe IMS-APEX2 experiment 
were compared to published mitochondrial protein database MitoCarta 2.0 (red). (D) Overlap of 
biotin-phenol labeled peptides enriched by BioSITe (yellow) with that from Hung et al. (blue). (E) 
Predicted topology of mitochondrial transmembrane proteins of translocase of inner mitochondrial 
membrane 50 (TIMM50) (top), NADH:ubiquinone oxidoreductase subunit A8 (NDUFB8) 
(middle), and coiled-coil domain containing 51 (CCDC51) (bottom). Matrix facing (orange), 
transmembrane (green), and intermembrane space domains are indicated. Cartoon depictions of 
these proteins embedded in the inner membrane (green) are shown in grey with biotinylation sites 
detected by BioSITe are colored in red and black detected by Lee et al. using the Matrix-APEX2 
construct. (F) Schematic overview of enrichment method for O-GlcNAcylated peptides. After LysC 
digestion, an azide-modified monosaccharide (GalNAz) is added to the O-GlcNAc motif using 
galactosyltransferase1 GalT1. Biotinylation of O-GlacNAc motif subsequently mediated by click 
chemistry reaction between the azide group and of GalNAz and the alkyne group of biotin DIBO 
alkene. Biotin is used to enrich peptides with O-GlcNAc motif using BioSITe (G) MS/MS spectra 
of a O-GlcNAc modified peptide corresponding to nuclear pore complex protein NUP153 
(NUP153). Ion peaks at m/z 216.08, 345.15 and 447.16, labeled signature ions, correspond to 
fragments from click chemistry reagents.  
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mitochondrial matrix (Matrix-APEX2) in conjunction with the IMS-APEX2 construct, 
one could map the parts of transmembrane proteins that have domains in the matrix and 
the IMS. In some cases, BioSITe was able to provide biotinylation sites that definitively 
allowed us to predict the topology of 29 mitochondrial proteins. For instance, translocase 
of inner mitochondrial membrane 50 (TIMM50) anchored in inner mitochondria 
membrane, BioSITe provided biotinylation sites of Y122, Y255, Y259, and Y301 at its 
C-terminus (Figure 4.4E, top). In agreement with our data, the C-terminus of TIMM50 
has been previously shown to be exposed to the IMS 86,87. Biotinylation of Y301 was also 
described by a different study by Lee et al using desthiobiotin-phenol as a molecular 
probe 84. In the case of NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8 
(NDUFB8), BioSITe identified biotinylation of Y161 at the C-terminus, thus confirming 
the previously resolved structure 88. Biotinylation of the IMS side in NDUFB8 was not 
identified by desthiobiotin-phenol-based analysis 84. Finally, in the case of a known 
mitochondrial protein, coiled coil domain containing protein 51 (CCDC51), whose 
topology has not yet been well characterized, BioSITe led to identification of a novel site 
at Y275, which is positioned between the two putative transmembrane domains thereby 
establishing its topology in the inner membrane of the mitochondria 89. As labeled by 
IMS-APEX2, we hypothesized that the region containing Y275 is located in the IMS. We 
also noticed that Y143 located at the N-terminus of CCDC51 has been annotated by 
Matrix-APEX 84, suggesting the CCDC51 is embedded in the mitochondrial inner 
membrane and the N terminus of CCDC51 is located inside the mitochondria matrix. 
Taken together, the observed site level information indicates an IMS linker bridging the 
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two transmembrane domains and the C terminus is also projecting into the matrix (Figure 
4.4E left).   
4.7 Applying BioSITe to biotin-based click chemistry 
To test the potentially broad applicability of BioSITe, we applied our method to a 
biotin-based click-chemistry strategy to identify the post-translational modification of 
serine and threonine residues by N-acetylglucosamine (O-GlcNAc) 90. O-GlcNAc is 
associated with a wide variety of cellular processes including cell cycle, stress response, 
transcription, and nutrient sensing 91,92. To detect O-GlcNAc modified residues, whole 
cell lysates from HEK293T cells were digested by the protease Lys-C and the resulting 
peptides were subjected to PNGase F and mutant β-1,4-galactosyltransferase (Gal-T1 
(Y289L)) treatment which lead to specific labeling of O-GlcNAc modified peptides with 
an additional sugar containing an azide (GalNAz) moiety, which is compatible with click 
chemistry (Figure 4.4F). These modified peptides were subsequently biotinylated in a 
second reaction by click chemistry using DIBO biotin alkyne where the azide group of 
UDP-GalNAz recruits the alkyne group attached to biotin 93,94. Peptides containing biotin 
were then captured using BioSITe for LC-MS/MS analysis. 
Our LC-MS/MS analysis identified O-GlcNAc sites on many known O-GlcNAc modified 
proteins including host cell factor 1 (HCFC1), nuclear pore complex protein 153 
(NUP153), nuclear pore complex protein 214 (NUP214) and nuclear pore complex 
protein 98 (NUP98) 95,96 (Supplementary Table 9). A total of 10 known O-GlcNAc sites 
were identified on HCF1 while 5 known sites were identified on NUP153. NUP153 is a 
nuclear pore protein with zinc finger domains which are critical for the recruitment of 
COP1 (coatomer complex protein 1) to the nuclear envelope. NUP153 is involved in the 
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breakdown of the nuclear envelope at the prophase of cell cycle 97. It has been shown that 
the level of O-GlcNAcylation at S529 increases dramatically upon phosphorylation of 
NUP153 at S534 by CDK1 during cell cycle 95. Figure 4G shows an MS/MS spectrum of 
an O-GlcNAc-modified peptide from NUP153. Click chemistry strategies are not limited 
to identification sites of glycosylated proteins but have many applications, in particular, 
recent studies of small molecule probes couple with click chemistry are enabling high-
throughput drug discovery 98,99. We anticipate that BioSITe could benefit these 
experiments as many existing reagents rely on biotin for enrichment by preclude site 
















Despite speculations regarding the roles of mammalian DGKs in modulating 
synaptic function, the function of DGKθ in the brain has remained unknown. The data 
presented in this thesis were designed to test the hypothesis that DGKθ modulates 
neurotransmitter release from central synapses. I found that DGKθ protein expression is 
coincident with synaptogenesis and localizes specifically to excitatory synapses. Both 
acute and chronic loss of DGKθ from cortical neurons resulted in slowed SV retrieval 
following neuronal stimulation. SV recycling kinetics could be rescued by ectopic 
expression of enzymatically active, but not inactive, DGKθ, thus, implicating DGKθ 
catalytic activity in promoting the efficient recycling of SVs following neuronal activity.  
5.1 BCR-ABL variant signaling 
Although BCR-ABL signaling has been intensively investigated for many years, a direct 
and systematic comparison of p190BCR-ABL and p210BCR-ABL signaling differences has 
never been undertaken.  In this study, we directly compared p190BCR-ABL and p210BCR-ABL 
protein-protein interactions and global protein phosphorylation signatures in homogenous 
cell culture systems that model early hematopoietic differentiation.  Our observations 
indicate many differences between p190BCR-ABL and p210BCR-ABL in signaling pathway 
regulation.  
In 1996, Ilaria and Van Etten,21 later confirmed in part by Druker and colleagues in 
2009,12 revealed one of the first pathways to be differentially regulated by p190BCR-ABL 
and p210BCR-ABL.  Both groups use immunoprecipitation and anti-phosphotyrosine 
immunoblotting to measure the total phosphorylation status of Stat proteins induced by 
both variants.  However, these analyses lacked tyrosine site-specific resolution, which we 
now provide. Our site-specific analyses provide a deeper understanding of the nature of 
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the differential regulation of Stat proteins.  Specifically, our analysis identified p190BCR-
ABL/p210BCR-ABL differential regulation of sites within the trans-activating domains of Stat 
proteins, that when phosphorylated, lead to dimerization and subsequent DNA binding.  
Our interaction analysis leads us to conclude that these differential phosphorylation 
signatures are likely mediated by differential interactions between Stat proteins and the 
two variants.  Stat proteins have a major role in normal hematopoiesis – for example, 
when Stat1 is deleted in mice, B lymphoid development is significantly reduced.100  This 
is potentially relevant to the p190BCR-ABL interaction and phosphorylation signatures 
observed in our study as p190BCR-ABL could be engaging Stat1 differently than p210BCR-ABL 
to drive the associated B cell phenotype.  Furthermore, Stat proteins have been revealed 
to be incredibly important for BCR-ABL mediated leukemogenesis. Specifically, both 
Stat3 and Stat5, found to exhibit preference for p210BCR-ABL interaction, are indispensable 
for the initiation of p210BCR-ABL leukemia and Stat5 is necessary for maintaining 
CML.101,102  In addition, Janus kinase 2 (Jak2), the upstream kinase targeting Stat5, has 
also been shown to be required for p190BCR-ABL to initiate leukemic transformation, while 
Jak2 is dispensable for p210BCR-ABL transformation55 suggesting that p190BCR-ABL/p210BCR-
ABL differential activation of Stat proteins is necessary for different phenotypes.  This is 
particularly relevant to our findings as the preferential direct interaction of Stat5 with 
p210BCR-ABL could circumvent the need of Jak2, where p190BCR-ABL requires an 
intermediary, Jak2, for leukemia initiation because it lacks this robust Stat5 interaction. 
We conclude Stat protein differential interaction, and potentially activation, associated 
with p190BCR-ABL and p210BCR-ABLappears to play a role in how the two variants drive 
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leukemia, in particular the apparent lineage preference (AML versus CML), and certainly 
warrants further investigation.   
Importantly, our analyses uncovered a potential differential subcellular localization as a 
feature of p190BCR-ABL and p210BCR-ABL unique signaling programs (Figure 5).  Because 
p190BCR-ABL lacks the PH domain, which mediates interactions with the plasma 
membrane, it may be free to associate more with the cytoskeleton. In support of this, we 
observed increased interaction of p190BCR-ABL with cytoskeletal modifiers such as 
Wiskott-Aldrich syndrome family members, hyperphosphorylation of many cytoskeletal 
proteins as well as others such as Dok1, Nck1, Nck2, Grb2, and SHIP2  that are involved 
in cytoskeletal reorganization.59,60  Differential interaction with cytoskeleton has 
previously been implicated in studies showing that p190BCR-ABL and p210BCR-ABL induced 
distinctly different cellular motilities.103,104  Strikingly, in support of our findings, 
previous data  provided evidence that  deletion of the C-terminal F-actin binding domain 
in p190BCR-ABL reduced its oncogenicity, while the same deletion in p210BCR-ABL appeared 
dispensable for establishing leukemia.46,47   
In contrast to an apparent preference of p190BCR-ABL with cytoskeletal components and 
regulators, p210BCR-ABL, which contains the PH domain, tends to interact with molecules 
that suggest its localization to be more proximal to the plasma membrane (Figure 5).  We 
identified p210BCR-ABL enriched interaction with Cbl, Cblb, SHIP1, SHIP2, Shc1, and 
Ubash3b which are all involved in the regulation of plasma membrane bound 
receptors.51,105,106  Ubash3b is a particularly interesting molecule that could be playing 
some role in attenuating certain functions of p210BCR-ABL, including SHIP1 degradation by 
inhibiting Cbl and binding to ubiquitinated proteins.   Moreover, Ubash3b has been  
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Figure 5. Model of differential p190BCR-ABL and p210BCR-ABL signaling. Interaction, determined 
by BioID interactome analysis, is by close proximity of ellipses.  Yellow coloring indicates proteins 
that are enriched in p190BCR-ABL interaction and blue coloring denote p210BCR-ABL enriched 
interaction.  Green/brown coloring indicates no detected interaction in BioID but are place near 
p190BCR-ABL based on their p190BCR-ABL hyperphosphorylation signature.  p210BCR-ABL is shown in 
dark blue to be anchored to the plasma membrane by the PH domain.  p190BCR-ABL is shown in 
orange to be anchored to the cytoskeleton by the F-acting binding domain interacting with 
molecules therein.  Dotted lines with arrowheads refer to molecular functions observed in previous 
studies.  Line with semicircle arrowhead represents the ubiquitin binding function of Ubash3b.  
Ubiquitin modifications (UB) are represented by green circles.  
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shown to have phosphatase activity toward some Src and Syk family tyrosine kinases52,107 
and we found evidence of  dysregulation of both Lyn and Syk in our analysis.   Src 
kinases have been shown to be required for the establishment of BCR-ABL positive B-
ALL while being dispensable for CML establishment in mouse models, stressing the 
importance of our data describing the p210BCR-ABL-specific preference for interactions 
with and regulation of Ubash3b and its downstream regulation of Src kinases.108   
Another interesting level of differential p190BCR-ABL/p210BCR-ABL regulation was found at 
the level of total proteome control.  In the MPP experiment we found a surprising amount 
of developmental and leukemia related proteins differentially regulated in p190BCR-ABL 
and p210BCR-ABL expressing cells.  Particularly, the presence of the myeloid/myeloid 
neoplasm centric proteins such as Runx1, Runx3, and myeloperoxidase associated with 
p210BCR-ABL cells and the presence of B cell centric proteins such as Tcf3 and Pbxip1 
associated with p190BCR-ABL cells is interesting.  The presence of CD34 on p210BCR-ABL 
and not p190BCR-ABL MPP cells is perhaps consistent with the observation that p190BCR-ABL 
requires a B cell differentiation event from the stem cell compartment to establish 
leukemia, while p210BCR-ABL leukemogenesis continually originates from stem cell 
compartment, in mouse models.109  
Reckel et al.110 have reported a similar study in this issue where they also examine 
differential signaling by p190BCR-ABL and p210BCR-ABL. Both studies have identified many 
of the same molecules to be differentially regulated by p190BCR-ABL and p210BCR-ABL, 
underscoring the reproducibility of global proteomic approaches to study signaling 
pathways in two different laboratories. However, there are also some minor differences 
that we believe are attributable to two broad areas - technical and biological. The 
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methods employed by each group had some differences; for example, different 
phosphopeptide enrichment strategies, mass spectrometers, search algorithms, 
quantification methods and methods for interactome analysis (BioID vs. affinity 
purification) were used. Of the two approaches used for interactome analysis, the BioID 
system is likely to detect direct interactions and might allow for detection of more 
transient interactions, while affinity purification methods might favor stronger 
biochemical interactions. Thus, taken together, both approaches to detect protein-protein 
interactions are somewhat complementary, as each method has its own biases for 
particular subsets of interactions, as has been previously shown.8 An important 
contributing factor to biological variation observed between the two studies is likely the 
relative expression level of the two variants in Ba/F3 cells.   
Regardless of the differences, the two studies were both able to highlight many of the 
same molecules and pathways, which have major relevance to understanding BCR-ABL 
biology.  Most prominent of which are the identification of p210BCR-ABL specific 
interaction of Ubash3b/Sts-1 by both affinity purification and BioID, differential 
regulation of members of the STAT and Src families, and the association of p190BCR-ABL 
with cytoskeletal elements, leading to a general conclusion that the variants may exhibit 
different subcellular localization or enrichment.  The differential phosphorylation 
signatures of Stat and Src family members are particularly attractive, as inhibition of 
these molecules could be further evaluated in the context of current tyrosine kinase 
inhibitor-based therapies targeting BCR-ABL, a strategy that would be especially 
important in the treatment of BCR-ABL positive ALL.      
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In summary, we have hypothesized that the disparate clinical and experimental 
phenotypes associated with the BCR-ABL variants likely originate from inherent 
differences in signaling.  Our findings in Ba/F3 and MPP cell lines represent a first 
glimpse into the complexity of how BCR-ABL variants differentially interface with 
hematopoiesis and drive leukemogenesis via their unique signaling programs.  We 
hypothesize that understanding how p190BCR-ABL and p210BCR-ABL differently regulate key 
signaling molecules will help explain the lineage preferences and lead to new therapeutic 
inroads.  Our data provide a clear set of differently regulated molecules to test in specific 
hematopoietic stages and in more clinically directed assays. 
5.2 BioSITe conclusions and future of interactomics 
We have shown that BioSITe permits enrichment and detection of biotinylated 
peptides including the localization of biotinylation sites within peptides. Using an 
isotopically labeled version of biotin, BioSITe allows for a quantitative analysis that is 
ideal for characterizing molecular differences across different biological conditions. 
Although, we have demonstrated the use of a four Dalton heavier version of biotin, which 
is commercially available, other biotin isotopologues can be generated that will allow for 
higher levels of multiplexing. The ability to obtain site level information in terms of 
biotinylation can provide spatial information regarding the architecture of protein 
complexes and topology of subcellular proteomes. We have also shown the broad 
applicability of BioSITe by applying this strategy to a biotin-based click chemistry 
strategy for identifying O-GlcNAc modified sites. Overall, BioSITe is an attractive 
option as a simpler strategy with a high yield than previously used methods, which relied 
on low yields of biotinylated peptides and, in some cases, a higher number of LC-MS/MS 
 78 
runs in-gel digests or customized molecular probes (e.g. desthiobiotin-phenol), which are 
out of the reach for most laboratories to generate. Additionally, the site level information 
provided in click chemistry approaches will circumvent the need for complicated 
cleavable tags that are frequently employed. Taken together, we foresee the general 
applicability of BioSITe in most applications that involve biotinylation as a strategy to 
tag proteins or post-translational modifications. While this paper was being finalized for 
publication, a report on a similar strategy using an antibody approach for direct 
enrichment of biotinylated peptide was published35. 
The effect BioSITe will have on the field of proximity dependent biotinylation 
assays still has some unknowns. The degree to which the site of biotinylation can predict 
the point of molecular contact of a PPI remains unclear. With the accumulation of more 
BioSITe datasets it is possible that trends will arise.  It is clear, however, the utility of the 
site of biotinylation has for the combination of membrane separated subcellular proteome 
mapping and BioSITe for predicting unknown trans-membrane containing protein 
topology.   
Beyond the site of biotinylation information provided by BioSITe the entirety of 
proximity dependent biotinylation methods in general have important implications of the 
future of detecting of PPIs.  Co-immunoprecipitation (Co-IP) experiments have 
traditionally been the method of choice for detecting PPIs. However, the overlap between 
BioID, for example, and Co-IP experiments has been shown to be more “complimentary” 
than overlapping8.  Comparing the BCR-ABL interactomes determine by Co-IP 
experiments by Reckel et al. and the BioID experiments described in this thesis both 




Figure 6. Venn diagram comparing Cutler et al. with Reckel et al. BioID and affinity purification 
interactome studies of BCR-ABL 
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BioID identified many more proteins than Co-IP, there are only 27 overlapping identities, 
and there are proteins uniquely identified in both methods, 162 for BioID and 24 for Co-
IP. Moreover, only one protein, Ubash3b, was found to be differentially interacting with 
p190BCR-ABL and p210BCR-ABL cells in both studies41,111. This suggests that proximity 
dependent labeling technologies and Co-IP experiments measure different properties a 
given protein’s interactome. Perhaps Co-IP measures the stronger “biochemical” 
interactions and the proximity-based methods capture where the protein has been and 
what are its neighbors.  It is incumbent on the field, through downstream biological 
experiments, to test putative interactors identified in both Co-IP and proximity-based 
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